Antigen Information
General Information of This Antigen
Antigen ID | TAR0THKZD |
|||||
---|---|---|---|---|---|---|
Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
|||||
Gene Name | ERBB2 |
|||||
Gene ID | ||||||
Synonym | HER2; MLN19; NEU; NGL; Metastatic lymph node gene 19 protein;Proto-oncogene Neu;Proto-oncogene c-ErbB-2;Tyrosine kinase-type cell surface receptor HER2;p185erbB2;CD_antigen=CD340 |
|||||
Sequence |
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV Click to Show/Hide
|
|||||
Family | Tyr protein family |
|||||
Function |
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
Click to Show/Hide
|
|||||
Uniprot Entry | ||||||
HGNC ID | ||||||
KEGG ID |
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADAPT6-ABD
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ADAPT6-ABD-mcDM1 |
Mertansine DM1 |
Microtubule (MT) |
Maleimidocaproyl (Ser3-Gly)3 |
[1] |
Anbenitamab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anbenitamab-ADC-Tb3-1 |
Anbenitamab-ADC-Tb3-1 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-1 linker |
[2] | |
Anbenitamab-ADC-Tb3-2 |
Anbenitamab-ADC-Tb3-2 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-2 linker |
[2] | |
Anbenitamab-ADC-Tb3-3 |
Anbenitamab-ADC-Tb3-3 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-3 linker |
[2] | |
Anbenitamab-ADC-Tb3-4 |
Anbenitamab-ADC-Tb3-4 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-4 linker |
[2] | |
Anbenitamab-ADC-Tb3-5 |
Anbenitamab-ADC-Tb3-5 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-5 linker |
[2] | |
Anbenitamab-ADC-Tb3-6 |
Anbenitamab-ADC-Tb3-6 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-6 linker |
[2] | |
Anbenitamab-ADC-Tb3-7 |
Anbenitamab-ADC-Tb3-7 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-7 linker |
[2] | |
Anbenitamab-ADC-Tb3-8 |
Anbenitamab-ADC-Tb3-8 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-8 linker |
[2] | |
Anbenitamab-ADC-Tb3-9 |
Anbenitamab-ADC-Tb3-9 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-9 linker |
[2] | |
Anbenitamab-ADC-Tb3-10 |
Anbenitamab-ADC-Tb3-10 payload |
Undisclosed |
Anbenitamab-ADC-Tb3-10 linker |
[2] |
ANG4043
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
An2-anti-HER2-Doxetaxel |
Docetaxel |
Microtubule (MT) |
Undisclosed |
[3] |
Anti-HER2 1-alpha-hydroxyvitamin-D5-HER-2 Anti-ody conjugate mAb
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Alpha-hydroxyvitamin-D5-HER2 antibody conjugate |
Vitamin D |
Undisclosed |
Sulfosuccinimidyl 6-4 azido nitrophenylamido hexanode (SANPAH) |
[4] |
Anti-HER2 7C2 mAb
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-5 ADC |
GNE-987 (R) |
Bromodomain-containing protein 4 (BRD4) |
Dolaflexin polymer |
[5] |
Anti-HER2 antibody 20507
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-28 |
WO2015095301A2 ADC-28 payload |
Undisclosed |
WO2015095301A2 ADC-28 linker |
[6] | |
WO2015095301A2 ADC-29 |
WO2015095301A2 ADC-29 payload |
Undisclosed |
WO2015095301A2 ADC-29 linker |
[6] | |
WO2015095301A2 ADC-30 |
WO2015095301A2 ADC-30 payload |
Undisclosed |
WO2015095301A2 ADC-30 linker |
[6] | |
WO2015095301A2 ADC-31 |
WO2015095301A2 ADC-31 payload |
Undisclosed |
WO2015095301A2 ADC-31 linker |
[6] | |
WO2015095301A2 ADC-32 |
WO2015095301A2 ADC-32 payload |
Undisclosed |
WO2015095301A2 ADC-32 linker |
[6] | |
WO2015095301A2 ADC-33 |
WO2015095301A2 ADC-33 payload |
Undisclosed |
WO2015095301A2 ADC-33 linker |
[6] | |
WO2015095301A2 ADC-34 |
WO2015095301A2 ADC-34 payload |
Undisclosed |
WO2015095301A2 ADC-34 linker |
[6] | |
WO2015095301A2 ADC-35 |
WO2015095301A2 ADC-35 payload |
Undisclosed |
WO2015095301A2 ADC-35 linker |
[6] | |
WO2015095301A2 ADC-36 |
WO2015095301A2 ADC-36 payload |
Undisclosed |
WO2015095301A2 ADC-36 linker |
[6] | |
WO2015095301A2 ADC-37 |
WO2015095301A2 ADC-37 payload |
Undisclosed |
WO2015095301A2 ADC-37 linker |
[6] | |
WO2015189791A1 ADC-27 |
WO2015189791A1 ADC-27 payload |
Undisclosed |
WO2015189791A1 ADC-27 linker |
[7] | |
WO2015189791A1 ADC-28 |
WO2015189791A1 ADC-28 payload |
Undisclosed |
WO2015189791A1 ADC-28 linker |
[7] | |
WO2015189791A1 ADC-29 |
WO2015189791A1 ADC-29 payload |
Undisclosed |
WO2015189791A1 ADC-29 linker |
[7] | |
WO2015189791A1 ADC-30 |
WO2015189791A1 ADC-30 payload |
Undisclosed |
WO2015189791A1 ADC-30 linker |
[7] | |
WO2015189791A1 ADC-31 |
WO2015189791A1 ADC-31 payload |
Undisclosed |
WO2015189791A1 ADC-31 linker |
[7] | |
WO2015189791A1 ADC-32 |
WO2015189791A1 ADC-32 payload |
Undisclosed |
WO2015189791A1 ADC-32 linker |
[7] | |
WO2015189791A1 ADC-33 |
WO2015189791A1 ADC-33 payload |
Undisclosed |
WO2015189791A1 ADC-33 linker |
[7] | |
WO2015189791A1 ADC-34 |
WO2015189791A1 ADC-34 payload |
Undisclosed |
WO2015189791A1 ADC-34 linker |
[7] | |
WO2015189791A1 ADC-35 |
WO2015189791A1 ADC-35 payload |
Undisclosed |
WO2015189791A1 ADC-35 linker |
[7] | |
WO2015189791A1 ADC-36 |
WO2015189791A1 ADC-36 payload |
Undisclosed |
WO2015189791A1 ADC-36 linker |
[7] | |
WO2015189791A1 ADC-37 |
WO2015189791A1 ADC-37 payload |
Undisclosed |
WO2015189791A1 ADC-37 linker |
[7] | |
WO2015189791A1 ADC-40 |
WO2015189791A1 ADC-40 payload |
Undisclosed |
WO2015189791A1 ADC-40 linker |
[7] | |
WO2015189791A1 ADC-61 |
WO2015189791A1 ADC-61 payload |
Undisclosed |
WO2015189791A1 ADC-61 linker |
[7] | |
WO2015189791A1 ADC-63 |
WO2015189791A1 ADC-63 payload |
Undisclosed |
WO2015189791A1 ADC-63 linker |
[7] | |
WO2015189791A1 ADC-64 |
WO2015189791A1 ADC-64 payload |
Undisclosed |
WO2015189791A1 ADC-64 linker |
[7] |
Anti-HER2 antibody 2H9-A121C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
2H9-A121C-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
2H9-A121C-BMPEO-DM1 linker |
[8] |
Anti-HER2 DVD-Fab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 DVD-Fab_MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Dibromomaleimide-PEG4 |
[9] |
Anti-HER2 DVD-Fab-h38c2-K99C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 DVD-Fab-h38c2-K99C_MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Dibromomaleimide-PEG4 |
[9] |
Anti-HER2 DVD-IgG1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 DVD-IgG1_MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Dibromomaleimide-PEG4 |
[9] | |
Anti-HER2 DVD-IgG1-Tiancimycin |
Tiancimycin |
Microtubule (MT) |
DVD-PEG4-Triazol |
[10] |
Anti-HER2 DVD-IgG1-H38c2-K99C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 DVD-IgG1-h38c2-K99C_MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Dibromomaleimide-PEG4 |
[9] | |
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 3 |
5(6)-Carboxytetramethylrhodamine |
Undisclosed |
Dibromomaleimide-PEG3 |
[9] | |
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 2 |
5(6)-Carboxytetramethylrhodamine |
Undisclosed |
Monobromomaleimide-PEG3 |
[9] | |
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 1 |
5(6)-Carboxytetramethylrhodamine |
Undisclosed |
Mal-PEG3 |
[9] | |
Anti-HER2 DVD-IgG1-h38c2-K99C Fluorescein |
Fluorescein derivative |
Undisclosed |
MS-PODA |
[9] |
Anti-HER2 IgG1(GH2-20)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-20)-vc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[11] |
Anti-HER2 IgG1(GH2-20) scFv
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
scFv(GH2-20)-PE38KDEL |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[11] |
Anti-HER2 IgG1(GH2-20)-AL1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-20)-AL1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[11] |
Anti-HER2 IgG1(GH2-61)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-61)-vc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[11] |
Anti-HER2 IgG1(GH2-61) scFv
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
scFv(GH2-61)-PE38KDEL |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[11] |
Anti-HER2 IgG1(GH2-61)-AL1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-61)-AL1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[11] |
Anti-HER2 IgG1(GH2-75)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-75)-vc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[11] |
Anti-HER2 IgG1(GH2-75) scFv
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
scFv(GH2-75)-PE38KDEL |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[11] |
Anti-HER2 IgG1(GH2-75)-AL1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (GH2-75)-AL1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[11] |
Anti-HER2 IgG1(H32)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (H32)-vc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[11] |
Anti-HER2 IgG1(H32) scFv
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
scFv(H32)-PE38KDEL |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[11] |
Anti-HER2 IgG1(H32)-AL1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (H32)-AL1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[11] |
Anti-HER2 mAb
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 ADC 12-3.1 |
Anti-HER2 ADC 12-3 payload |
Undisclosed |
Anti-HER2 ADC 12-3 linker |
[12] | |
Anti-HER2 ADC 2-7 |
Anti-HER2 ADC 2-7 payload |
Undisclosed |
Anti-HER2 ADC 2-7 linker |
[12] | |
Anti-HER2 ADC 3-4 |
Anti-HER2 ADC 3-4 payload |
Undisclosed |
Anti-HER2 ADC 3-4 linker |
[12] | |
Anti-HER2 ADC 4-3 |
Anti-HER2 ADC 4-3 payload |
Undisclosed |
Anti-HER2 ADC 4-3 linker |
[12] | |
Anti-HER2 ADC 5-3 |
Anti-HER2 ADC 5-3 payload |
Undisclosed |
Anti-HER2 ADC 5-3 linker |
[12] | |
Anti-HER2 ADC 6-2 |
Anti-HER2 ADC 6-2 payload |
Undisclosed |
Anti-HER2 ADC 6-2 linker |
[12] | |
Anti-HER2 ADC 7-1 |
Anti-HER2 ADC 7-1 payload |
Undisclosed |
Anti-HER2 ADC 7-1 linker |
[12] | |
Anti-HER2 ADC 8-5 |
Anti-HER2 ADC 8-5 payload |
Undisclosed |
Anti-HER2 ADC 8-5 linker |
[12] | |
Anti-HER2 ADC 9-4 |
Anti-HER2 ADC 9-4 payload |
Undisclosed |
Anti-HER2 ADC 9-4 linker |
[12] | |
Anti-HER2 ADC 10-1 |
Anti-HER2 ADC 10-1 payload |
Undisclosed |
Anti-HER2 ADC 10-1 linker |
[12] | |
Anti-HER2 ADC 11-5 |
Anti-HER2 ADC 11-5 payload |
Undisclosed |
Anti-HER2 ADC 11-5 linker |
[12] | |
Anti-HER2 ADC 12-3.2 |
Anti-HER2 ADC 12-3 payload |
Undisclosed |
Anti-HER2 ADC 12-3 linker |
[12] | |
Anti-HER2 ADC 13-7 |
Anti-HER2 ADC 13-7 payload |
Undisclosed |
Anti-HER2 ADC 13-7 linker |
[12] | |
Anti-HER2 ADC 14-5 |
Anti-HER2 ADC 14-5 payload |
Undisclosed |
Anti-HER2 ADC 14-5 linker |
[12] | |
Anti-HER2 ADC 15-5 |
Anti-HER2 ADC 15-5 payload |
Undisclosed |
Anti-HER2 ADC 15-5 linker |
[12] | |
Anti-HER2 ADC 16-5 |
Anti-HER2 ADC 16-5 payload |
Undisclosed |
Anti-HER2 ADC 16-5 linker |
[12] | |
Anti-HER2 ADC 17-2 |
Anti-HER2 ADC 17-2 payload |
Undisclosed |
Anti-HER2 ADC 17-2 linker |
[12] | |
Anti-HER2 ADC 18-3 |
Anti-HER2 ADC 18-3 payload |
Undisclosed |
Anti-HER2 ADC 18-3 linker |
[12] | |
Anti-HER2 ADC 19-5 |
Anti-HER2 ADC 19-5 payload |
Undisclosed |
Anti-HER2 ADC 19-5 linker |
[12] | |
Anti-HER2 ADC 20-5 |
Anti-HER2 ADC 20-5 payload |
Undisclosed |
Anti-HER2 ADC 20-5 linker |
[12] | |
Anti-HER2 ADC 21-5 |
Anti-HER2 ADC 21-5 payload |
Undisclosed |
Anti-HER2 ADC 21-5 linker |
[12] | |
ADC2202 |
Undisclosed |
Undisclosed |
Undisclosed |
[13] | |
Alpha-HER2-Duo 405 |
Duocarmycin 405 |
Human Deoxyribonucleic acid (hDNA) |
Undisclosed |
[12] | |
HER2-HC-H-SS-PBD |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
H-disulfide linker |
[14] | |
HER2-LC-H-SS-PBD |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
H-disulfide linker |
[14] | |
HER2-HC-Me-SS-PBD |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
Me-disulfide linker |
[14] | |
HER2-LC-Me-SS-PBD |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
Me-disulfide linker |
[14] | |
Anti-HER2 mAb-Compound 9 |
Mertansine DM1 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 9 linker |
[15] | |
Anti-HER2 mAb-Compound 17 |
Mertansine DM4 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 17 linker |
[15] | |
Anti-HER2 mAb-Compound 25 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 25 linker |
[15] | |
Anti-HER2 mAb-Compound 31 |
Auristatin 0101 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 31 linker |
[15] | |
Anti-HER2 mAb-Compound 36 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 36 linker |
[15] | |
Anti-HER2 mAb-Compound 43 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Anti-HER2 mAb-Compound 43 linker |
[15] | |
Anti-HER2 mAb-Compound 49 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Anti-HER2 mAb-Compound 49 linker |
[15] | |
Anti-HER2 mAb-Compound 55 |
Mertansine DM1 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 55 linker |
[15] | |
Anti-HER2 mAb-Compound 59 |
Mertansine DM4 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 59 linker |
[15] | |
Anti-HER2 mAb-Compound 64 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 64 linker |
[15] | |
Anti-HER2 mAb-Compound 69 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 69 linker |
[15] | |
Anti-HER2 mAb-Compound 74 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Anti-HER2 mAb-Compound 74 linker |
[15] | |
Anti-HER2 mAb-Compound 75 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 75 linker |
[15] | |
Anti-HER2 mAb-Compound 76 |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER2 mAb-Compound 76 linker |
[15] | |
Anti-HER2 mAb-Compound 77 |
Mertansine DM1 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 77 linker |
[15] | |
Anti-HER2 mAb-Compound 78 |
Auristatin 0101 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 78 linker |
[15] | |
Anti-HER2 mAb-Compound 79 |
Auristatin 0101 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 79 linker |
[15] | |
Anti-HER2 mAb-Compound 80 |
Mertansine DM4 |
Microtubule (MT) |
Anti-HER2 mAb-Compound 80 linker |
[15] | |
CN110997010A ADC-1 |
CN110997010A ADC-1 payload |
Undisclosed |
CN110997010A ADC-1 linker |
[16] | |
CN110997010A ADC-2 |
CN110997010A ADC-2 payload |
Undisclosed |
CN110997010A ADC-2 linker |
[16] | |
CN110997010A ADC-3 |
CN110997010A ADC-3 payload |
Undisclosed |
CN110997010A ADC-3 linker |
[16] | |
CN110997010A ADC-4 |
CN110997010A ADC-4 payload |
Undisclosed |
CN110997010A ADC-4 linker |
[16] | |
CN110997010A ADC-5 |
CN110997010A ADC-5 payload |
Undisclosed |
CN110997010A ADC-5 linker |
[16] | |
CN110997010A ADC-6 |
CN110997010A ADC-6 payload |
Undisclosed |
CN110997010A ADC-6 linker |
[16] | |
CN110997010A ADC-7 |
CN110997010A ADC-7 payload |
Undisclosed |
CN110997010A ADC-7 linker |
[16] | |
CN110997010A ADC-8 |
CN110997010A ADC-8 payload |
Undisclosed |
CN110997010A ADC-8 linker |
[16] |
Anti-HER2 mAb A114N
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
A114N-Mc-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[17] |
Anti-HER2 mAb A114N NNAS
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
A114N NNAS-Mc-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[17] |
Anti-HER2 mAb glutamine 295 (Q295)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
VCit ADC 3a |
Monomethyl auristatin F |
Microtubule (MT) |
DBCO-PEG-VCit-PABC |
[18] | |
EVCit ADC 3c |
Monomethyl auristatin F |
Microtubule (MT) |
DBCO-PEG-EVCit-PABC |
[18] |
Anti-HER2 mAb H-1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
H-1-vcMMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[19] |
Anti-HER2 mAb H-3
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
H-3-vcMMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[19] |
Anti-HER2 mAb H-4
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
H-4-vcMMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[19] |
Anti-HER2 mAb H32
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
H32-DM1_3.0 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[20] | |
H32-DM1_3.3 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[20] | |
H32-DM1_3.7 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[20] | |
H32-DM1_3.8 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[20] | |
H32-VCMMAE_2.1 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[20] | |
H32-VCMMAE_3.2 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[20] | |
H32-VCMMAE_3.8 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[20] | |
H32-VCMMAE_6.6 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[20] |
Anti-HER2 mAb NNAS
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
NNAS-Mc-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[17] |
Anti-HER2 mAb S298N/T299A/Y300S
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2 S298N/T299A/Y300S-Mc-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[17] |
Anti-HER2 mAb WT
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2 WT-Mc-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[17] | |
Anti-HER-AO-Cys-MC-VC-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Anti-HER-AO-Cys-MC-VC-PABC-MMAE linker |
[17] | |
Anti-HER-MC-VC-PABC-PEG8-Dol10 |
Anti-HER-MC-VC-PABC-PEG8-Dol10 payload |
Undisclosed |
Anti-HER-MC-VC-PABC-PEG8-Dol10 linker |
[17] | |
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10 |
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10 payload |
Undisclosed |
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10 linker |
[17] |
Anti-HER2 NJH395 mAb
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
NJH-395 |
Tolllike receptor 7 agonist |
Toll-like receptor 7 (TLR7) |
Noncleavable linker |
[21] |
Anti-HER2 scFv-Fc (Ser396Sec)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2 scFv-Fc (Ser396Sec)-CN29 |
Monomethyl auristatin F derivative peptide (CN29) |
Microtubule (MT) |
Lodoacetamido-caproyl |
[22] |
Anti-HER2-D265C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anti-HER2-D265C-30.2060 |
Amanitin 30.206 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
Anti-HER2-D265C-30.2115 |
Amanitin 30.2115 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
Anti-HER2-D265C-30.2347 |
Amanitin 30.2347 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
Anti-HER2-D265C-30.1699 |
Amanitin 30.1699 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
Anti-HER2-D265C-30.2371 |
Amanitin 30.2371 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
Anti-HER2-D265C-30.0880 |
Amanitin 30.088 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Maleimido-caproyl |
[23] | |
Anti-HER2-D265C-30.2867 |
Amanitin 30.2867 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Maleimido-caproyl |
[23] |
Anti-HER2/neu mAb 4D5
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
4D5-AF (CUAAC) |
Auristatin F |
Microtubule (MT) |
N6-(2-azidoethoxy)carbonyl-L-lysine |
[24] |
Anti-human HER2 mAb
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-EC4 DAR7.8 |
NAMPT inhibitor 5 |
Nicotinamide phosphoribosyltransferase (NAMPT) |
Open-chain glycine maleimide |
[25] | |
HER2-EC5 |
NAMPT inhibitor 6 |
Nicotinamide phosphoribosyltransferase (NAMPT) |
Open-chain glycine maleimide-PEG |
[25] | |
HER2-EC4 DAR2.7 |
NAMPT inhibitor 5 |
Nicotinamide phosphoribosyltransferase (NAMPT) |
Open-chain glycine maleimide |
[25] | |
HER2-EC3 |
NAMPT inhibitor 4 |
Nicotinamide phosphoribosyltransferase (NAMPT) |
Mc-Val-Ala |
[25] | |
HER2-EC1 |
NAMPT inhibitor 4 |
Nicotinamide phosphoribosyltransferase (NAMPT) |
Maleimido-caproyl |
[25] |
Anvatabart
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Anvatabart pactil |
Undisclosed |
Undisclosed |
Undisclosed |
[26] |
Az-LacNAc-Tras Ab7
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-41 |
Monomethyl auristatin E |
Microtubule (MT) |
Bicyclononyne derivative 6e |
[27] | |
HER2-gsADC-42 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6l |
[27] | |
HER2-gsADC-43 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6m |
[27] | |
HER2-gsADC-44 |
Monomethyl auristatin E |
Microtubule (MT) |
Noncleavable linker 6s |
[27] | |
HER2-gsADC-45 |
Monomethyl auristatin E |
Microtubule (MT) |
Noncleavable linker 6t |
[27] |
Azido-tagged trastuzumab (Ab2)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-5 |
Monomethyl auristatin E |
Microtubule (MT) |
Azadibenzocylooctyne-amine derivative 6d |
[27] | |
HER2-gsADC-6 |
Monomethyl auristatin E |
Microtubule (MT) |
Bicyclononyne derivative 6e |
[27] | |
HER2-gsADC-7 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6m |
[27] | |
HER2-gsADC-8 |
Monomethyl auristatin E |
Microtubule (MT) |
Glycosyl PEGylation linker 6r |
[27] |
Azido-tagged trastuzumab (Ab3)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-9 |
Monomethyl auristatin E |
Microtubule (MT) |
Linear alkyne 6f |
[27] | |
HER2-gsADC-10 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6g |
[27] | |
HER2-gsADC-11 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6h |
[27] | |
HER2-gsADC-12 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6i |
[27] | |
HER2-gsADC-13 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6j |
[27] | |
HER2-gsADC-14 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6k |
[27] | |
HER2-gsADC-15 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6l |
[27] | |
HER2-gsADC-16 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6m |
[27] | |
HER2-gsADC-17 |
Monomethyl auristatin E |
Microtubule (MT) |
Noncleavable linker 6t |
[27] |
Azido-tagged trastuzumab (Ab5)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-22 |
Monomethyl auristatin E |
Microtubule (MT) |
Linear alkyne 6f |
[27] | |
HER2-gsADC-23 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6g |
[27] | |
HER2-gsADC-24 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6h |
[27] | |
HER2-gsADC-25 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6i |
[27] | |
HER2-gsADC-26 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6j |
[27] | |
HER2-gsADC-27 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6k |
[27] | |
HER2-gsADC-28 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6l |
[27] | |
HER2-gsADC-29 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6m |
[27] | |
HER2-gsADC-30 |
Monomethyl auristatin E |
Microtubule (MT) |
Glycosyl PEGylation linker 6o |
[27] | |
HER2-gsADC-31 |
Monomethyl auristatin E |
Microtubule (MT) |
Glycosyl PEGylation linker 6p |
[27] | |
HER2-gsADC-32 |
Monomethyl auristatin E |
Microtubule (MT) |
Glycosyl PEGylation linker 6q |
[27] | |
HER2-gsADC-33 |
Monomethyl auristatin E |
Microtubule (MT) |
Glycosyl PEGylation linker 6r |
[27] |
Azido-tagged trastuzumab (Ab6)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-34 |
Monomethyl auristatin E |
Microtubule (MT) |
Linear alkyne 6f |
[27] | |
HER2-gsADC-35 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6g |
[27] | |
HER2-gsADC-36 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6h |
[27] | |
HER2-gsADC-37 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6i |
[27] | |
HER2-gsADC-38 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6j |
[27] | |
HER2-gsADC-39 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6k |
[27] | |
HER2-gsADC-40 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6l |
[27] |
BA-130-00-01
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC |
LC A032D/HC payload |
Undisclosed |
LC A032D/HC linker |
[28] |
BA-130-03-02
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC Y052K |
LC A032D/HC Y052K payload |
Undisclosed |
LC A032D/HC Y052K linker |
[28] |
BA-130-03-05
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC G056K |
LC A032D/HC G056K payload |
Undisclosed |
LC A032D/HC G056K linker |
[28] |
BA-130-03-06
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC T058D |
LC A032D/HC T058D payload |
Undisclosed |
LC A032D/HC T058D linker |
[28] |
BA-130-03-07
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC A106E |
LC A032D/HC A106E payload |
Undisclosed |
LC A032D/HC A106E linker |
[28] |
BA-130-03-08
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LC A032D/HC S119E |
LC A032D/HC S119E payload |
Undisclosed |
LC A032D/HC S119E linker |
[28] |
BAT0606
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
BAT-8001 |
Maytansinoid derivative |
Microtubule (MT) |
6-Maleimidocaproic acid |
[29] |
BAY-865
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2 KSP-ADC 1.1 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 1 |
[30] | |
HER2 KSP-ADC 1.2 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 2 |
[30] | |
HER2 KSP-ADC 1.3 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 3 |
[30] | |
HER2 KSP-ADC 1.4 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 4 |
[30] | |
HER2 KSP-ADC 2.1 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 5 |
[30] | |
HER2 KSP-ADC 2.2 |
Pyrrole based kinesin spindle protein inhibitor |
Kinesin-like protein KIF11 (KIF11) |
Kinesin spindle protein inhibitor (KSPi)-ADC linker 6 |
[30] |
CHO-G2F-Tras (Ab4)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-18 |
Monomethyl auristatin E |
Microtubule (MT) |
ThioPz linker 6a |
[27] | |
HER2-gsADC-19 |
Monomethyl auristatin E |
Microtubule (MT) |
2-Aminobenzamide oxime |
[27] | |
HER2-gsADC-20 |
Monomethyl auristatin E |
Microtubule (MT) |
Hydroxylamine derivative 6c |
[27] | |
HER2-gsADC-21 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6n |
[27] |
CHO-S2G2F-Tras (Ab1)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-gsADC-1 |
Monomethyl auristatin E |
Microtubule (MT) |
ThioPz linker 6a |
[27] | |
HER2-gsADC-2 |
Monomethyl auristatin E |
Microtubule (MT) |
2-Aminobenzamide oxime |
[27] | |
HER2-gsADC-3 |
Monomethyl auristatin E |
Microtubule (MT) |
Hydroxylamine derivative 6c |
[27] | |
HER2-gsADC-4 |
Monomethyl auristatin E |
Microtubule (MT) |
PEGylation linker 6n |
[27] |
CN105828840B_ADC-102 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-102 |
CN105828840B_ADC-102 payload |
Undisclosed |
CN105828840B_ADC-102 linker |
[31] |
CN105828840B_ADC-103 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-103 |
CN105828840B_ADC-103 payload |
Undisclosed |
CN105828840B_ADC-103 linker |
[31] |
CN105828840B_ADC-105 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-105 |
CN105828840B_ADC-105 payload |
Undisclosed |
CN105828840B_ADC-105 linker |
[31] |
CN105828840B_ADC-106 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-106 |
CN105828840B_ADC-106 payload |
Undisclosed |
CN105828840B_ADC-106 linker |
[31] |
CN105828840B_ADC-107 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-107 |
CN105828840B_ADC-107 payload |
Undisclosed |
CN105828840B_ADC-107 linker |
[31] |
CN105828840B_ADC-109 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-109 |
CN105828840B_ADC-109 payload |
Undisclosed |
CN105828840B_ADC-109 linker |
[31] |
CN105828840B_ADC-112 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-112 |
CN105828840B_ADC-112 payload |
Undisclosed |
CN105828840B_ADC-112 linker |
[31] |
CN105828840B_ADC-113 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-113 |
CN105828840B_ADC-113 payload |
Undisclosed |
CN105828840B_ADC-113 linker |
[31] |
CN105828840B_ADC-114 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-114 |
CN105828840B_ADC-114 payload |
Undisclosed |
CN105828840B_ADC-114 linker |
[31] |
CN105828840B_ADC-117 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-117 |
CN105828840B_ADC-117 payload |
Undisclosed |
CN105828840B_ADC-117 linker |
[31] |
CN105828840B_ADC-118 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-118 |
CN105828840B_ADC-118 payload |
Undisclosed |
CN105828840B_ADC-118 linker |
[31] |
CN105828840B_ADC-119 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-119 |
CN105828840B_ADC-119 payload |
Undisclosed |
CN105828840B_ADC-119 linker |
[31] |
CN105828840B_ADC-121 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-121 |
CN105828840B_ADC-121 payload |
Undisclosed |
CN105828840B_ADC-121 linker |
[31] |
CN105828840B_ADC-123 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
CN105828840B ADC-123 |
CN105828840B_ADC-123 payload |
Undisclosed |
CN105828840B_ADC-123 linker |
[31] |
Coprelotamab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Coprelotamab-ADC-Tb3-1 |
Coprelotamab-ADC-Tb3-1 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-1 linker |
[2] | |
Coprelotamab-ADC-Tb3-2 |
Coprelotamab-ADC-Tb3-2 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-2 linker |
[2] | |
Coprelotamab-ADC-Tb3-3 |
Coprelotamab-ADC-Tb3-3 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-3 linker |
[2] | |
Coprelotamab-ADC-Tb3-4 |
Coprelotamab-ADC-Tb3-4 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-4 linker |
[2] | |
Coprelotamab-ADC-Tb3-5 |
Coprelotamab-ADC-Tb3-5 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-5 linker |
[2] | |
Coprelotamab-ADC-Tb3-6 |
Coprelotamab-ADC-Tb3-6 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-6 linker |
[2] | |
Coprelotamab-ADC-Tb3-7 |
Coprelotamab-ADC-Tb3-7 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-7 linker |
[2] | |
Coprelotamab-ADC-Tb3-8 |
Coprelotamab-ADC-Tb3-8 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-8 linker |
[2] | |
Coprelotamab-ADC-Tb3-9 |
Coprelotamab-ADC-Tb3-9 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-9 linker |
[2] | |
Coprelotamab-ADC-Tb3-10 |
Coprelotamab-ADC-Tb3-10 payload |
Undisclosed |
Coprelotamab-ADC-Tb3-10 linker |
[2] |
DP001
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
DP-303c |
Monomethyl auristatin E |
Microtubule (MT) |
PEG2-Val-Cit-PABC |
[32] |
DVD-IgG
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
177Lu-CHX-A"-DTPA-PODS-DVD |
Lutetium-177 |
Undisclosed |
PODS-CHX-A"-DTPA |
[33] |
DX-CHO9
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
DX126-262 |
Tubulysin B derivative |
Microtubule (MT) |
Undisclosed |
[34] |
Engineered trastuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Trastuzumab-C239I-SG3600 |
N10-beta-glucuronide SG3200 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[35] | |
Trastuzumab-C239I-SG3400 |
SG3200 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[35] | |
Engineered HER-SG3227 |
SG2219 |
Human Deoxyribonucleic acid (hDNA) |
Acetamide-PEG4-Val-Ala-PABA |
[36] |
Gancotamab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Gancotamab-ADC-Tb3-1 |
Gancotamab-ADC-Tb3-1 payload |
Undisclosed |
Gancotamab-ADC-Tb3-1 linker |
[2] | |
Gancotamab-ADC-Tb3-2 |
Gancotamab-ADC-Tb3-2 payload |
Undisclosed |
Gancotamab-ADC-Tb3-2 linker |
[2] | |
Gancotamab-ADC-Tb3-3 |
Gancotamab-ADC-Tb3-3 payload |
Undisclosed |
Gancotamab-ADC-Tb3-3 linker |
[2] | |
Gancotamab-ADC-Tb3-4 |
Gancotamab-ADC-Tb3-4 payload |
Undisclosed |
Gancotamab-ADC-Tb3-4 linker |
[2] | |
Gancotamab-ADC-Tb3-5 |
Gancotamab-ADC-Tb3-5 payload |
Undisclosed |
Gancotamab-ADC-Tb3-5 linker |
[2] | |
Gancotamab-ADC-Tb3-6 |
Gancotamab-ADC-Tb3-6 payload |
Undisclosed |
Gancotamab-ADC-Tb3-6 linker |
[2] | |
Gancotamab-ADC-Tb3-7 |
Gancotamab-ADC-Tb3-7 payload |
Undisclosed |
Gancotamab-ADC-Tb3-7 linker |
[2] | |
Gancotamab-ADC-Tb3-8 |
Gancotamab-ADC-Tb3-8 payload |
Undisclosed |
Gancotamab-ADC-Tb3-8 linker |
[2] | |
Gancotamab-ADC-Tb3-9 |
Gancotamab-ADC-Tb3-9 payload |
Undisclosed |
Gancotamab-ADC-Tb3-9 linker |
[2] | |
Gancotamab-ADC-Tb3-10 |
Gancotamab-ADC-Tb3-10 payload |
Undisclosed |
Gancotamab-ADC-Tb3-10 linker |
[2] |
H01L02
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2022228495A1 ADC-73 |
WO2022228495A1 ADC-73 payload |
Undisclosed |
WO2022228495A1 ADC-73 linker |
[37] |
HER2-C Anti-ody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-C Antibody-Compound (X) |
HER2-C Antibody-Compound (X) payload |
Undisclosed |
HER2-C Antibody-Compound (X) linker |
[38] | |
HER2-C Antibody-Compound (XI) |
HER2-C Antibody-Compound (XI) payload |
Undisclosed |
HER2-C Antibody-Compound (XI) linker |
[38] | |
HER2-C Antibody-Compound (XIV) |
HER2-C Antibody-Compound (XIV) payload |
Undisclosed |
HER2-C Antibody-Compound (XIV) linker |
[38] | |
HER2-C Antibody-Compound (XVIII) |
HER2-C Antibody-Compound (XVIII) payload |
Undisclosed |
HER2-C Antibody-Compound (XVIII) linker |
[38] | |
HER2-C Antibody-Compound (Ie) |
HER2-C Antibody-Compound (Ie) payload |
Undisclosed |
HER2-C Antibody-Compound (Ie) linker |
[38] | |
HER2-C Antibody-Compound (XIX) |
HER2-C Antibody-Compound (XIX) payload |
Undisclosed |
HER2-C Antibody-Compound (XIX) linker |
[38] | |
HER2-C Antibody-Compound (Ii) |
HER2-C Antibody-Compound (Ii) payload |
Undisclosed |
HER2-C Antibody-Compound (Ii) linker |
[38] | |
HER2-C Antibody-Compound (XLI) |
HER2-C Antibody-Compound (XLI) payload |
Undisclosed |
HER2-C Antibody-Compound (XLI) linker |
[38] | |
HER2-C Antibody-Compound (XVI) |
HER2-C Antibody-Compound (XIX) payload |
Undisclosed |
HER2-C Antibody-Compound (XIX) linker |
[38] | |
HER2-C Antibody-Compound (XL) |
HER2-C Antibody-Compound (XL) payload |
Undisclosed |
HER2-C Antibody-Compound (XL) linker |
[38] | |
HER2-C Antibody-Compound (XLII) |
HER2-C Antibody-Compound (XLII) payload |
Undisclosed |
HER2-C Antibody-Compound (XLII) linker |
[38] | |
HER2-C Antibody-Compound (XV) |
HER2-C Antibody-Compound (XV) payload |
Undisclosed |
HER2-C Antibody-Compound (XV) linker |
[38] | |
HER2-C Antibody-Compound (XLIII) |
HER2-C Antibody-Compound (XLIII) payload |
Undisclosed |
HER2-C Antibody-Compound (XLIII) linker |
[38] |
Hertuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Disitamab vedotin |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[39] | |
Hertuzumab vedotin |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[40] | |
Disitamab-ADC-Tb3-1 |
Disitamab-ADC-Tb3-1 payload |
Undisclosed |
Disitamab-ADC-Tb3-1 linker |
[2] | |
Disitamab-ADC-Tb3-2 |
Disitamab-ADC-Tb3-2 payload |
Undisclosed |
Disitamab-ADC-Tb3-2 linker |
[2] | |
Disitamab-ADC-Tb3-3 |
Disitamab-ADC-Tb3-3 payload |
Undisclosed |
Disitamab-ADC-Tb3-3 linker |
[2] | |
Disitamab-ADC-Tb3-4 |
Disitamab-ADC-Tb3-4 payload |
Undisclosed |
Disitamab-ADC-Tb3-4 linker |
[2] | |
Disitamab-ADC-Tb3-5 |
Disitamab-ADC-Tb3-5 payload |
Undisclosed |
Disitamab-ADC-Tb3-5 linker |
[2] | |
Disitamab-ADC-Tb3-6 |
Disitamab-ADC-Tb3-6 payload |
Undisclosed |
Disitamab-ADC-Tb3-6 linker |
[2] | |
Disitamab-ADC-Tb3-7 |
Disitamab-ADC-Tb3-7 payload |
Undisclosed |
Disitamab-ADC-Tb3-7 linker |
[2] | |
Disitamab-ADC-Tb3-8 |
Disitamab-ADC-Tb3-8 payload |
Undisclosed |
Disitamab-ADC-Tb3-8 linker |
[2] | |
Disitamab-ADC-Tb3-9 |
Disitamab-ADC-Tb3-9 payload |
Undisclosed |
Disitamab-ADC-Tb3-9 linker |
[2] | |
Disitamab-ADC-Tb3-10 |
Disitamab-ADC-Tb3-10 payload |
Undisclosed |
Disitamab-ADC-Tb3-10 linker |
[2] |
HS627
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ZV0203 |
Duostatin 5 |
Human Deoxyribonucleic acid (hDNA) |
Undisclosed |
[41] |
hu4DFabv7
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv7-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv7-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (A121C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (A121C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (A121C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-A175C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-A175C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-A175C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-A40C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-A40C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-A40C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-A88C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-A88C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-A88C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-S119C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-S119C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-S119C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-S122C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-S122C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-S122C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (H-S179C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (H-S179C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (H-S179C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (L-A144C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (L-A144C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (L-A144C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (L-A43C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (L-A43C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (L-A43C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (L-S168C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (L-S168C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (L-S168C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (L-V15C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (L-V15C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (L-V15C)-BMPEO-DM1 linker |
[8] |
hu4DFabv8 (V110C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
hu4DFabv8 (V110C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
hu4DFabv8 (V110C)-BMPEO-DM1 linker |
[8] | |
hu4DFabv8 (V110C)-MC-MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Maleimido-caproyl |
[8] | |
hu4DFabv8 (V110C)-MC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Maleimido-caproyl |
[8] | |
hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[8] | |
hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[8] |
Isoprenylated trastuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
LCB-ADC1 |
Monomethyl auristatin F |
Microtubule (MT) |
Isoprene-PEG3-beta-Glu-PABC |
[42] | |
LCB-ADC3 |
Monomethyl auristatin F |
Microtubule (MT) |
Bridged PEG4-valine-alanine |
[42] | |
LCB-ADC2 |
Monomethyl auristatin F |
Microtubule (MT) |
Isoprene-PEG3,3,3-beta-Glu-PABC |
[42] |
MAB802
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
MRG-002 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[43] |
Margetuximab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Margetuximab-ADC-Tb3-1 |
Margetuximab-ADC-Tb3-1 payload |
Undisclosed |
Margetuximab-ADC-Tb3-1 linker |
[2] | |
Margetuximab-ADC-Tb3-2 |
Margetuximab-ADC-Tb3-2 payload |
Undisclosed |
Margetuximab-ADC-Tb3-2 linker |
[2] | |
Margetuximab-ADC-Tb3-3 |
Margetuximab-ADC-Tb3-3 payload |
Undisclosed |
Margetuximab-ADC-Tb3-3 linker |
[2] | |
Margetuximab-ADC-Tb3-4 |
Margetuximab-ADC-Tb3-4 payload |
Undisclosed |
Margetuximab-ADC-Tb3-4 linker |
[2] | |
Margetuximab-ADC-Tb3-5 |
Margetuximab-ADC-Tb3-5 payload |
Undisclosed |
Margetuximab-ADC-Tb3-5 linker |
[2] | |
Margetuximab-ADC-Tb3-6 |
Margetuximab-ADC-Tb3-6 payload |
Undisclosed |
Margetuximab-ADC-Tb3-6 linker |
[2] | |
Margetuximab-ADC-Tb3-7 |
Margetuximab-ADC-Tb3-7 payload |
Undisclosed |
Margetuximab-ADC-Tb3-7 linker |
[2] | |
Margetuximab-ADC-Tb3-8 |
Margetuximab-ADC-Tb3-8 payload |
Undisclosed |
Margetuximab-ADC-Tb3-8 linker |
[2] | |
Margetuximab-ADC-Tb3-9 |
Margetuximab-ADC-Tb3-9 payload |
Undisclosed |
Margetuximab-ADC-Tb3-9 linker |
[2] | |
Margetuximab-ADC-Tb3-10 |
Margetuximab-ADC-Tb3-10 payload |
Undisclosed |
Margetuximab-ADC-Tb3-10 linker |
[2] |
MHES0488A
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
RG-6148 |
Pyrrolo[2,1-c][1,4]benzodiazepine monoamide (PBD-MA) |
Human Deoxyribonucleic acid (hDNA) |
Methyl-disulfide linker |
[44] |
Mil40
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Mil40-12B |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based linker 12B |
[45] | |
Mil40-5 |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mc-Val-Ala-PABC |
[46] | |
Mil40-6 |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mal-PEG2-Val-Ala-PABC |
[46] | |
Mil40-7 |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mal-PEG4-Val-Ala-PABC |
[46] | |
Mil40-8 |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mal-PEG8-Val-Ala-PABC |
[46] | |
Mil40-12A |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based linker 12A |
[45] | |
Mil40-12C |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based linker 12C |
[45] | |
Mil40-11 (DAR=7.1) |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mc-PEG8-Val-Ala-PABC |
[46] | |
Mil40-11 (DAR=3.8) |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Mc-PEG8-Val-Ala-PABC |
[46] | |
Mil40-12B |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[45] | |
Cys-linker-MMAE-based ADC 11 |
Monomethyl auristatin E |
Microtubule (MT) |
Cys-11 ADC linker |
[47] | |
Cys-linker-MMAE-based ADC 12 |
Monomethyl auristatin E |
Microtubule (MT) |
Cys-12 ADC linker |
[47] | |
Cys-linker-MMAE-based ADC 13 |
Monomethyl auristatin E |
Microtubule (MT) |
Cys-13 ADC linker |
[47] | |
Cys-linker-MMAE-based ADC 14 |
Monomethyl auristatin E |
Microtubule (MT) |
Cys-14 ADC linker |
[47] | |
Cys-linker-MMAE-based ADC 15 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-PABC |
[47] | |
Cys-linker-MMAE-based ADC 16 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[47] | |
ADC Mil40-6 |
Monomethyl auristatin E |
Microtubule (MT) |
Silyl ether-based linker |
[48] | |
Mil40-15 |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-PABC |
[47] | |
Trastuzumab biosimilar mil40 12a |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based Val-Ala-PABC linker 12a |
[49] | |
Trastuzumab biosimilar mil40 12b |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based Val-Ala-PABC linker 12b |
[49] | |
Trastuzumab biosimilar mil40 12c |
Monomethyl auristatin E |
Microtubule (MT) |
Maleamic methyl ester-based Val-Cit-PABC linker 12c |
[49] |
Modified pAcPhe trastuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ARX-788 |
Monomethyl auristatin F |
Microtubule (MT) |
Hydroxylamine-PEG4 |
[50] |
Modified ZHER2:2891 protein (ZHER2)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Pyro-Linker-ZHER2 |
Pyropheophorbide-a |
Undisclosed |
Pyro-Linker based linker |
[51] |
Patritumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2022228495A1 ADC-72 |
WO2022228495A1 ADC-72 payload |
Undisclosed |
WO2022228495A1 ADC-72 linker |
[37] |
Pertuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Pertuzumab zuvotolimod |
Maytansinoid derivative |
Microtubule (MT) |
Undisclosed |
[52] | |
WO2020063676A1 ADC-7 |
WO2020063676A1_ADC-7 payload |
Undisclosed |
WO2020063676A1_ADC-7 linker |
[53] | |
WO2020063676A1 ADC-8 |
WO2020063676A1_ADC-8 payload |
Undisclosed |
WO2020063676A1_ADC-8 linker |
[53] | |
WO2020063676A1 ADC-9 |
WO2020063676A1_ADC-9 payload |
Undisclosed |
WO2020063676A1_ADC-9 linker |
[53] | |
Pertuzumab-ADC-Tb3-1 |
Pertuzumab-ADC-Tb3-1 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-1 linker |
[2] | |
Pertuzumab-ADC-Tb3-2 |
Pertuzumab-ADC-Tb3-2 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-2 linker |
[2] | |
Pertuzumab-ADC-Tb3-3 |
Pertuzumab-ADC-Tb3-3 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-3 linker |
[2] | |
Pertuzumab-ADC-Tb3-4 |
Pertuzumab-ADC-Tb3-4 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-4 linker |
[2] | |
Pertuzumab-ADC-Tb3-5 |
Pertuzumab-ADC-Tb3-5 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-5 linker |
[2] | |
Pertuzumab-ADC-Tb3-6 |
Pertuzumab-ADC-Tb3-6 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-6 linker |
[2] | |
Pertuzumab-ADC-Tb3-7 |
Pertuzumab-ADC-Tb3-7 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-7 linker |
[2] | |
Pertuzumab-ADC-Tb3-8 |
Pertuzumab-ADC-Tb3-8 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-8 linker |
[2] | |
Pertuzumab-ADC-Tb3-9 |
Pertuzumab-ADC-Tb3-9 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-9 linker |
[2] | |
Pertuzumab-ADC-Tb3-10 |
Pertuzumab-ADC-Tb3-10 payload |
Undisclosed |
Pertuzumab-ADC-Tb3-10 linker |
[2] | |
Pertuzumab-Compound(la) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Pertuzumab-Compound(la) linker |
[54] | |
Pertuzumab-Compound (la) DAR 8 |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (la) DAR 8 linker |
[54] | |
Pertuzumab-Compound(lc) |
NeoDegrader P4 |
Protein cereblon (CRBN) |
Pertuzumab-Compound(lc) linker |
[54] | |
Pertuzumab-Compound (lc) DAR 8 |
NeoDegrader P4 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lc) DAR 8 linker |
[54] | |
Pertuzumab-Compound (le) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (le) linker |
[54] | |
Pertuzumab-Compound (lf) |
NeoDegrader P6 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lf) linker |
[54] | |
Pertuzumab-Compound (lg) |
NeoDegrader P2 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lg) linker |
[54] | |
Pertuzumab-Compound (lh) |
NeoDegrader P13 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lh) linker |
[54] | |
Pertuzumab-Compound (li) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (li) linker |
[54] | |
Pertuzumab-Compound (lk) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lk) linker |
[54] | |
Pertuzumab-Compound (ll) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (ll) linker |
[54] | |
Pertuzumab-Compound (lm) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lm) linker |
[54] | |
Pertuzumab-Compound (X) |
Pertuzumab-Compound (X) payload |
Undisclosed |
Pertuzumab-Compound (X) linker |
[38] | |
Pertuzumab-Compound (XI) |
Pertuzumab-Compound (XI) payload |
Undisclosed |
Pertuzumab-Compound (XI) linker |
[38] | |
Pertuzumab-Compound (XIV) |
Pertuzumab-Compound (XIV) payload |
Undisclosed |
Pertuzumab-Compound (XIV) linker |
[38] | |
Pertuzumab-Compound (XVIII) |
Pertuzumab-Compound (XVIII) payload |
Undisclosed |
Pertuzumab-Compound (XVIII) linker |
[38] | |
Pertuzumab-Compound (Ie) |
Pertuzumab-Compound (Ie) payload |
Undisclosed |
Pertuzumab-Compound (Ie) linker |
[38] | |
Pertuzumab-Compound (XIX) |
Pertuzumab-Compound (XIX) payload |
Undisclosed |
Pertuzumab-Compound (XIX) linker |
[38] | |
Pertuzumab-Compound (Ii) |
Pertuzumab-Compound (Ii) payload |
Undisclosed |
Pertuzumab-Compound (Ii) linker |
[38] | |
Pertuzumab-Compound (XLI) |
Pertuzumab-Compound (XLI) payload |
Undisclosed |
Pertuzumab-Compound (XLI) linker |
[38] | |
Pertuzumab-Compound (XVI) |
Pertuzumab-Compound (XIX) payload |
Undisclosed |
Pertuzumab-Compound (XIX) linker |
[38] | |
Pertuzumab-Compound (XL) |
Pertuzumab-Compound (XL) payload |
Undisclosed |
Pertuzumab-Compound (XL) linker |
[38] | |
Pertuzumab-Compound (XLII) |
Pertuzumab-Compound (XLII) payload |
Undisclosed |
Pertuzumab-Compound (XLII) linker |
[38] | |
Pertuzumab-Compound (XV) |
Pertuzumab-Compound (XV) payload |
Undisclosed |
Pertuzumab-Compound (XV) linker |
[38] | |
Pertuzumab-Compound (lj) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Pertuzumab-Compound (lj) linker |
[54] | |
Pertuzumab-Compound (XLIII) |
Pertuzumab-Compound (XLIII) payload |
Undisclosed |
Pertuzumab-Compound (XLIII) linker |
[38] | |
Pertuzumab-Compound 9 |
Mertansine DM1 |
Microtubule (MT) |
Pertuzumab-Compound 9 linker |
[15] | |
Pertuzumab-Compound 17 |
Mertansine DM4 |
Microtubule (MT) |
Pertuzumab-Compound 17 linker |
[15] | |
Pertuzumab-Compound 25 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 25 linker |
[15] | |
Pertuzumab-Compound 31 |
Auristatin 0101 |
Microtubule (MT) |
Pertuzumab-Compound 31 linker |
[15] | |
Pertuzumab-Compound 36 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 36 linker |
[15] | |
Pertuzumab-Compound 43 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Pertuzumab-Compound 43 linker |
[15] | |
Pertuzumab-Compound 49 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Pertuzumab-Compound 49 linker |
[15] | |
Pertuzumab-Compound 55 |
Mertansine DM1 |
Microtubule (MT) |
Pertuzumab-Compound 55 linker |
[15] | |
Pertuzumab-Compound 59 |
Mertansine DM4 |
Microtubule (MT) |
Pertuzumab-Compound 59 linker |
[15] | |
Pertuzumab-Compound 64 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 64 linker |
[15] | |
Pertuzumab-Compound 69 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 69 linker |
[15] | |
Pertuzumab-Compound 74 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Pertuzumab-Compound 74 linker |
[15] | |
Pertuzumab-Compound 75 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 75 linker |
[15] | |
Pertuzumab-Compound 76 |
Monomethyl auristatin E |
Microtubule (MT) |
Pertuzumab-Compound 76 linker |
[15] | |
Pertuzumab-Compound 77 |
Mertansine DM1 |
Microtubule (MT) |
Pertuzumab-Compound 77 linker |
[15] | |
Pertuzumab-Compound 78 |
Auristatin 0101 |
Microtubule (MT) |
Pertuzumab-Compound 78 linker |
[15] | |
Pertuzumab-Compound 79 |
Auristatin 0101 |
Microtubule (MT) |
Pertuzumab-Compound 79 linker |
[15] | |
Pertuzumab-Compound 80 |
Mertansine DM4 |
Microtubule (MT) |
Pertuzumab-Compound 80 linker |
[15] |
Pertuzumab-S239C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
HER2-A Antibody-Compound (X) |
HER2-A Antibody-Compound (X) payload |
Undisclosed |
HER2-A Antibody-Compound (X) linker |
[38] | |
HER2-A Antibody-Compound (XI) |
HER2-A Antibody-Compound (XI) payload |
Undisclosed |
HER2-A Antibody-Compound (XI) linker |
[38] | |
HER2-A Antibody-Compound (XIV) |
HER2-A Antibody-Compound (XIV) payload |
Undisclosed |
HER2-A Antibody-Compound (XIV) linker |
[38] | |
HER2-A Antibody-Compound (XVIII) |
HER2-A Antibody-Compound (XVIII) payload |
Undisclosed |
HER2-A Antibody-Compound (XVIII) linker |
[38] | |
HER2-A Antibody-Compound (Ie) |
HER2-A Antibody-Compound (Ie) payload |
Undisclosed |
HER2-A Antibody-Compound (Ie) linker |
[38] | |
HER2-A Antibody-Compound (XIX) |
HER2-A Antibody-Compound (XIX) payload |
Undisclosed |
HER2-A Antibody-Compound (XIX) linker |
[38] | |
HER2-A Antibody-Compound (Ii) |
HER2-A Antibody-Compound (Ii) payload |
Undisclosed |
HER2-A Antibody-Compound (Ii) linker |
[38] | |
HER2-A Antibody-Compound (XLI) |
HER2-A Antibody-Compound (XLI) payload |
Undisclosed |
HER2-A Antibody-Compound (XLI) linker |
[38] | |
HER2-A Antibody-Compound (XVI) |
HER2-A Antibody-Compound (XIX) payload |
Undisclosed |
HER2-A Antibody-Compound (XIX) linker |
[38] | |
HER2-A Antibody-Compound (XL) |
HER2-A Antibody-Compound (XL) payload |
Undisclosed |
HER2-A Antibody-Compound (XL) linker |
[38] | |
HER2-A Antibody-Compound (XLII) |
HER2-A Antibody-Compound (XLII) payload |
Undisclosed |
HER2-A Antibody-Compound (XLII) linker |
[38] | |
Pertuzumab-S239C-Compound (XV) |
Pertuzumab-S239C-Compound (XV) payload |
Undisclosed |
Pertuzumab-S239C-Compound (XV) linker |
[38] | |
HER2-A Antibody-Compound (XLIII) |
HER2-A Antibody-Compound (XLIII) payload |
Undisclosed |
HER2-A Antibody-Compound (XLIII) linker |
[38] |
Rat IgG2a mAb ICR12
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Monoclonal antibody ICR12-CPG2 conjugate |
Carboxypeptidase G2 (CPG2) |
Undisclosed |
Undisclosed |
[55] |
T-(kK183C+K290C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
PF-06804103 |
Auristatin 0101 |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[56] |
Thio Anti-HER2 hu7C2 HC L177C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017059289A1 ADC-117 |
WO2017059289A1_ADC-117 payload |
Undisclosed |
WO2017059289A1_ADC-117 linker |
[57] |
Thio Anti-HER2 hu7C2 HC Y376C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017059289A1 ADC-119 |
WO2017059289A1_ADC-119 payload |
Undisclosed |
WO2017059289A1_ADC-119 linker |
[57] |
Thio Anti-HER2 hu7C2 LC K149C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017059289A1 ADC-101 |
WO2017059289A1_ADC-101 payload |
Undisclosed |
WO2017059289A1_ADC-101 linker |
[57] | |
WO2017059289A1 ADC-102 |
WO2017059289A1_ADC-102 payload |
Undisclosed |
WO2017059289A1_ADC-102 linker |
[57] | |
WO2017059289A1 ADC-104 |
WO2017059289A1_ADC-104 payload |
Undisclosed |
WO2017059289A1_ADC-104 linker |
[57] | |
WO2017059289A1 ADC-106 |
WO2017059289A1_ADC-106 payload |
Undisclosed |
WO2017059289A1_ADC-106 linker |
[57] | |
WO2017059289A1 ADC-108 |
WO2017059289A1_ADC-108 payload |
Undisclosed |
WO2017059289A1_ADC-108 linker |
[57] | |
WO2017059289A1 ADC-109 |
WO2017059289A1_ADC-109 payload |
Undisclosed |
WO2017059289A1_ADC-109 linker |
[57] | |
WO2017059289A1 ADC-201 |
WO2017059289A1_ADC-201 payload |
Undisclosed |
WO2017059289A1_ADC-201 linker |
[57] | |
WO2017059289A1 ADC-203 |
WO2017059289A1_ADC-203 payload |
Undisclosed |
WO2017059289A1_ADC-203 linker |
[57] | |
WO2017059289A1 ADC-205 |
WO2017059289A1_ADC-205 payload |
Undisclosed |
WO2017059289A1_ADC-205 linker |
[57] |
Thio Anti-HER2 hu7C2 LC K149C HC L177C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017059289A1 ADC-113 |
WO2017059289A1_ADC-113 payload |
Undisclosed |
WO2017059289A1_ADC-113 linker |
[57] |
Thio Anti-HER2 hu7C2 LC K149C HC L177C HC Y376C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017059289A1 ADC-114 |
WO2017059289A1_ADC-114 payload |
Undisclosed |
WO2017059289A1_ADC-114 linker |
[57] |
Thio hu Anti-HER2 4D5-8 HC A118C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2014159981A2 ADC-211 |
WO2014159981A2_ADC-211 payload |
Undisclosed |
WO2014159981A2_ADC-211 linker |
[58] | |
WO2014159981A2 ADC-130 |
WO2014159981A2_ADC-130 payload |
Undisclosed |
WO2014159981A2_ADC-130 linker |
[58] | |
WO2014159981A2 ADC-HER2-48 |
WO2014159981A2_ADC-HER2-48 payload |
Undisclosed |
WO2014159981A2_ADC-HER2-48 linker |
[58] | |
WO2014159981A2 ADC-HER2-22 |
WO2014159981A2_ADC-HER2-22 payload |
Undisclosed |
WO2014159981A2_ADC-HER2-22 linker |
[58] |
Thio hu Anti-HER2 7C2 HC A140C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017214024A1 ADC-106 |
WO2017214024A1_ADC-106 payload |
Undisclosed |
WO2017214024A1_ADC-106 linker |
[59] |
Thio hu Anti-HER2 7C2 LC K149C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2017214024A1 ADC-103 |
WO2017214024A1_ADC-103 payload |
Undisclosed |
WO2017214024A1_ADC-103 linker |
[59] |
Thio-Tmab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Thio-Tmab-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
Thio-Tmab-BMPEO-DM1 linker |
[8] |
Thio-Tr (A121C)
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Thio-Tr (A121C)-BMPEO-DM1 |
Maytansinoid DM1 |
Microtubule (MT) |
Thio-Tr (A121C)-BMPEO-DM1 linker |
[8] |
Tigatuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Tigatuzumab-ADC-Tb3-1 |
Tigatuzumab-ADC-Tb3-1 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-1 linker |
[2] | |
Tigatuzumab-ADC-Tb3-2 |
Tigatuzumab-ADC-Tb3-2 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-2 linker |
[2] | |
Tigatuzumab-ADC-Tb3-3 |
Tigatuzumab-ADC-Tb3-3 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-3 linker |
[2] | |
Tigatuzumab-ADC-Tb3-4 |
Tigatuzumab-ADC-Tb3-4 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-4 linker |
[2] | |
Tigatuzumab-ADC-Tb3-5 |
Tigatuzumab-ADC-Tb3-5 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-5 linker |
[2] | |
Tigatuzumab-ADC-Tb3-6 |
Tigatuzumab-ADC-Tb3-6 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-6 linker |
[2] | |
Tigatuzumab-ADC-Tb3-7 |
Tigatuzumab-ADC-Tb3-7 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-7 linker |
[2] | |
Tigatuzumab-ADC-Tb3-8 |
Tigatuzumab-ADC-Tb3-8 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-8 linker |
[2] | |
Tigatuzumab-ADC-Tb3-9 |
Tigatuzumab-ADC-Tb3-9 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-9 linker |
[2] | |
Tigatuzumab-ADC-Tb3-10 |
Tigatuzumab-ADC-Tb3-10 payload |
Undisclosed |
Tigatuzumab-ADC-Tb3-10 linker |
[2] |
Trastuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Trastuzumab deruxtecan |
DX-8951 derivative (DXd) |
DNA topoisomerase 1 (TOP1) |
Mc-Gly-Gly-Phe-Gly |
[60] | |
Trastuzumab emtansine |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[61] | |
A-166 |
Duostatin 5 |
Human Deoxyribonucleic acid (hDNA) |
K-lock-Val-Cit-PABC |
[62] | |
Trastuzumab duocarmazine |
seco-DUBA |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer |
[63] | |
LCB14-0110 |
Monomethyl auristatin F |
Microtubule (MT) |
Geranyl ketone pyrophosphate oxime ligation |
[64] | |
SHR-A1811 |
SHR9265 |
DNA topoisomerase 1 (TOP1) |
Mc-Gly-Gly-Phe-Gly |
[65] | |
B-003 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[66] | |
GQ-1001 |
Mertansine DM1 |
Microtubule (MT) |
MCC-Gly6-Thr-Glu3-Pro-Leu-Ala3-Leu |
[67] | |
BDC-1001 |
TORL7/8 agonist T785 |
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8) |
BG based linker |
[68] | |
SHR-A1201 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[69] | |
MI-130004 |
PM050489 |
Microtubule (MT) |
6-(2,5-dioxopyrrol-1-yl)-N-Propylhexanamide |
[70] | |
ST8176AA1 |
ST7612AA1 |
Histone deacetylase 1 (HDAC1) |
Maleimide-thiol linker |
[71] | |
LIN-002 |
Undisclosed |
Undisclosed |
Undisclosed |
[72] | |
HER2 targeted DEP conjugate |
Active metabolite of irinotecan SN38 |
DNA topoisomerase 1 (TOP1) |
Undisclosed |
[73] | |
Tra-IR700 |
IRDye 700DX |
Undisclosed |
Undisclosed |
[74] | |
Anti-HER2 antibody-drug conjugate (Spirea) |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[75] | |
Trastuzumab-PNU-159682 Antibody-Drug Conjugate |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
Undisclosed |
[76] | |
PRO-1102 |
Exatecan |
DNA topoisomerase 1 (TOP1) |
Cleavable hydrophilic linker |
[77] | |
Trastuzumab-ATAC |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Undisclosed |
[78] | |
Trastuzumab-deBouganin |
DeBouganin |
Microtubule (MT) |
Undisclosed |
[79] | |
Trastuzumab-SYNtansine |
Ahx-maytansine |
Microtubule (MT) |
BCN-HydraSpace-Val-Cit-PABC |
[80] | |
Anti-HER2_vc-1 |
TLR7 agonist-1 |
Toll-like receptor 7 (TLR7) |
Mc-Val-Cit-PABC |
[81] | |
Tmab-SPP-DM1 |
Mertansine DM1 |
Microtubule (MT) |
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP) |
[82] | |
Tmab-SSNPP-DM3 |
Maytansinoid DM3 |
Microtubule (MT) |
Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP) |
[82] | |
Tmab-SSNPP-DM4 |
Mertansine DM4 |
Microtubule (MT) |
Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP) |
[82] | |
Trastuzumab-AJICAP-maytansinoid |
Mertansine DM1 |
Microtubule (MT) |
AJICAP |
[83] | |
Trastuzumab-C239I-SG3249 |
SG3199 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[84] | |
Tras-Gly5-EDA-Pnu |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
Gly5-EDA |
[85] | |
Trastuzumab DVD-ADC |
Monomethyl auristatin F |
Microtubule (MT) |
Hexapeptide linker ASTKGP |
[86] | |
Trastuzumab-RSL3-NH2 |
RSL3-NH2 |
Phospholipid hydroperoxide glutathione peroxidase (GPX4) |
Mal-PEG4-DBCO-Ala-Val |
[87] | |
Tras-Gly5-EDA-Dox |
Doxorubicin |
DNA topoisomerase 2-alpha (TOP2A) |
Gly5-EDA |
[85] | |
Tras-Gly5-EDA-Nemo |
Nemorubicin |
DNA topoisomerase 2-alpha (TOP2A) |
Gly5-EDA |
[85] | |
Tras-Gly3-Vakl-Cit-PAB-PNU-159682 |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
Gly3-vcPAB |
[85] | |
Tras-Gly5-May |
Mertansine DM1 |
Microtubule (MT) |
Gly5 |
[85] | |
Trastuzumab-SG3227 |
SG2219 |
Human Deoxyribonucleic acid (hDNA) |
Acetamide-PEG4-Val-Ala-PABA |
[36] | |
HER-SG3249 |
SG3199 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[88] | |
Site-specific HER-SG3249 |
SG3199 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[88] | |
Trastuzumab-SG3600 high DAR |
N10-beta-glucuronide SG3200 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[35] | |
Trastuzumab vedotin |
Undisclosed |
Undisclosed |
Undisclosed |
[89] | |
Trastuzumab rezetecan |
Undisclosed |
Undisclosed |
Undisclosed |
[90] | |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Gly-Calicheamicin |
Gly-calicheamicin |
Human Deoxyribonucleic acid (hDNA) |
BCN-HydraSpace-Val-Cit-PABC |
[80] | |
Trastuzumab SG-3259 |
SG3312 |
Human Deoxyribonucleic acid (hDNA) |
Mc-Val-Ala |
[91] | |
Trastuzumab-SG3400 high DAR |
SG3200 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[35] | |
Anti-HER2_vc-7 |
TLR7 agonist-7 |
Toll-like receptor 7 (TLR7) |
Mc-Val-Cit-PABC |
[81] | |
Anti-HER2_vc-2 |
TLR7 agonist-2 |
Toll-like receptor 7 (TLR7) |
Mc-Val-Cit-PABC |
[81] | |
TTZ-Mc-NPV-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Asn-Pro-Val-PABC |
[92] | |
Adcitmer |
Monomethyl auristatin E |
Microtubule (MT) |
Pyridino-caproic-Val-Cit-PABC |
[93] | |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
BCN-HydraSpace-Val-Cit-PABC |
[80] | |
MF-TTZ-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Dibromomethyl pyridine-Val-Cit-PABC |
[94] | |
FGM-TTZ-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[94] | |
NC-ADC |
Monomethyl auristatin E |
Microtubule (MT) |
Divinylpyrimidine-PEG4 |
[95] | |
C-ADC |
Monomethyl auristatin E |
Microtubule (MT) |
Divinylpyrimidine-PEG4-Val-Ala-PABC |
[95] | |
Tmab-SPDP-DM1 |
Mertansine DM1 |
Microtubule (MT) |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB) |
[82] | |
T-C-F (DAR 3.7) |
Monomethyl auristatin F |
Microtubule (MT) |
Maleimido-caproyl |
[96] | |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-PNU-159682 |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
BCN-HydraSpace-Val-Cit-PABC |
[97] | |
Tra-Exa-PSAR10 |
Exatecan |
DNA topoisomerase 1 (TOP1) |
Mal-Exa-PSAR10 |
[98] | |
Tra-Exa-PSAR0 |
Exatecan |
DNA topoisomerase 1 (TOP1) |
Mal-Exa-PSAR0 |
[98] | |
T-N-F (DAR 3.2) |
Aldehyde-tagged MMAF |
Microtubule (MT) |
Undisclosed |
[96] | |
T-N-F (DAR 1.6) |
Aldehyde-tagged MMAF |
Microtubule (MT) |
Undisclosed |
[96] | |
Tras-ALN |
Alendronate |
Farnesyl pyrophosphate synthase (FDPS) |
Bicyclo[6.1.0]nona-4-yne |
[99] | |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Duocarmycin |
Duocarmycin Sa |
Human Deoxyribonucleic acid (hDNA) |
BCN-HydraSpace-Val-Cit-PABC |
[80] | |
Trastuzumab-BCN-HydraSpace-Val-Ala-PABC-PBD dimer |
PBD dimer 2 |
Human Deoxyribonucleic acid (hDNA) |
BCN-HydraSpace-Val-Ala-PABC |
[80] | |
Trastuzumab-DNA mimic 4 |
Q Pho-DNA mimics |
Human Deoxyribonucleic acid (hDNA) |
Diphenyltio-Mal-Cap |
[100] | |
Trastuzumab-L3-TL |
Triptolide |
Nuclear factor NF-kappa-B p105 subunit (NFKB1) |
BVP-PEG3-carbamate-PEG4 |
[101] | |
Trastuzumab-L2-TL |
Triptolide |
Nuclear factor NF-kappa-B p105 subunit (NFKB1) |
BVP-PEG3-diamine |
[101] | |
Trastuzumab-L1-TL |
Triptolide |
Nuclear factor NF-kappa-B p105 subunit (NFKB1) |
BVP-PEG3-carbamate |
[101] | |
Trastuzumab-PNUEDAGly5 |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
LPETG-Gly5-EDA |
[102] | |
ADC2-2 |
ADC 2-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-2 linker |
[103] | |
ADC2-4 |
ADC 2-4 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-4 linker |
[103] | |
ADC2-6-2 |
ADC 2-6-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-6-2 linker |
[103] | |
ADC2-7-2 |
ADC 2-7-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-7-2 linker |
[103] | |
ADC2-9-1 |
ADC 2-9-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-9-1 linker |
[103] | |
ADC2-9-2 |
ADC 2-9-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-9-2 linker |
[103] | |
ADC2-10 |
ADC 2-10 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-10 linker |
[103] | |
ADC2-11 |
ADC 2-11 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-11 linker |
[103] | |
ADC2-22 |
ADC 2-22 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-22 linker |
[103] | |
ADC2-23 |
ADC 2-23 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-23 linker |
[103] | |
ADC2-24 |
ADC 2-24 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-24 linker |
[103] | |
ADC2-25 |
ADC 2-25 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-25 linker |
[103] | |
ADC2-26 |
ADC 2-26 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-26 linker |
[103] | |
ADC2-27 |
ADC 2-27 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-27 linker |
[103] | |
ADC2-29 |
ADC 2-29 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-29 linker |
[103] | |
ADC2-30 |
ADC 2-30 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-30 linker |
[103] | |
ADC2-31 |
ADC 2-31 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-31 linker |
[103] | |
ADC2-32 |
ADC 2-32 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-32 linker |
[103] | |
ADC2-33 |
ADC 2-33 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-33 linker |
[103] | |
ADC2-34 |
ADC 2-34 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-34 linker |
[103] | |
ADC2-35 |
ADC 2-35 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-35 linker |
[103] | |
ADC2-36-1 |
ADC 2-36-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-36-1 linker |
[103] | |
ADC2-36-2 |
ADC 2-36-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-36-2 linker |
[103] | |
ADC2-37 |
ADC 2-37 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-37 linker |
[103] | |
ADC2-38 |
ADC 2-38 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-38 linker |
[103] | |
ADC2-39 |
ADC 2-39 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-39 linker |
[103] | |
ADC2-40 |
ADC 2-40 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-40 linker |
[103] | |
ADC2-41 |
ADC 2-41 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-41 linker |
[103] | |
ADC2-42 |
ADC 2-42 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-42 linker |
[103] | |
ADC2-42-RO |
ADC 2-42-RO payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-42-RO linker |
[103] | |
ADC2-43 |
ADC 2-43 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-43 linker |
[103] | |
ADC2-44 |
ADC 2-44 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-44 linker |
[103] | |
ADC2-45 |
ADC 2-45 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-45 linker |
[103] | |
ADC2-46 |
ADC 2-46 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-46 linker |
[103] | |
ADC2-47 |
ADC 2-47 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-47 linker |
[103] | |
ADC2-48 |
ADC 2-48 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-48 linker |
[103] | |
ADC2-49 |
ADC 2-49 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-49 linker |
[103] | |
ADC2-50 |
ADC 2-50 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-50 linker |
[103] | |
ADC2-51 |
ADC 2-51 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-51 linker |
[103] | |
ADC2-53 |
ADC 2-53 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-53 linker |
[103] | |
ADC2-54 |
ADC 2-54 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-54 linker |
[103] | |
ADC2-55 |
ADC 2-55 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-55 linker |
[103] | |
ADC2-56 |
ADC 2-56 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-56 linker |
[103] | |
ADC2-57 |
ADC 2-57 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-57 linker |
[103] | |
ADC2-58 |
ADC 2-58 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-58 linker |
[103] | |
ADC2-59 |
ADC 2-59 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-59 linker |
[103] | |
ADC2-60 |
ADC 2-60 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-60 linker |
[103] | |
ADC2-61 |
ADC 2-61 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-61 linker |
[103] | |
ADC-2-62-1 |
ADC 2-62-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-62-1 linker |
[103] | |
ADC-2-62-2 |
ADC 2-62-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-62-2 linker |
[103] | |
ADC-2-63-1 |
ADC 2-63-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-63-1 linker |
[103] | |
ADC-2-63-2 |
ADC 2-63-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-63-2 linker |
[103] | |
ADC-2-64-1 |
ADC 2-64-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-64-1 linker |
[103] | |
ADC-2-64-2 |
ADC 2-64-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-64-2 linker |
[103] | |
ADC-2-65-1 |
ADC 2-65-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-65-1 linker |
[103] | |
ADC-2-65-2 |
ADC 2-65-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-65-2 linker |
[103] | |
ADC3-1 |
ADC 3-1 payload |
DNA topoisomerase 1 (TOP1) |
ADC 3-1 linker |
[103] | |
ADC3-2 |
ADC 3-2 payload |
DNA topoisomerase 1 (TOP1) |
ADC 3-2 linker |
[103] | |
ADC3-3 |
ADC 3-3 payload |
DNA topoisomerase 1 (TOP1) |
ADC 3-3 linker |
[103] | |
ADC3-4 |
ADC 3-4 payload |
DNA topoisomerase 1 (TOP1) |
ADC 3-4 linker |
[103] | |
ADC3-5 |
ADC 3-5 payload |
DNA topoisomerase 1 (TOP1) |
ADC 3-5 linker |
[103] | |
ADC2-A |
ADC 2-A payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-A linker |
[103] | |
ADC2-B |
ADC 2-B payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-B linker |
[103] | |
ADC2-12 |
ADC 2-12 payload |
DNA topoisomerase 1 (TOP1) |
ADC 2-12 linker |
[103] | |
HER2-ADC-01 (DAR8) |
HER2-ADC-01(DAR8) payload |
Undisclosed |
HER2-ADC-01(DAR8) linker |
[2] | |
HER2-ADC-02 (DAR8) |
HER2-ADC-02(DAR8) payload |
Undisclosed |
HER2-ADC-02(DAR8) linker |
[2] | |
HER2-ADC-03 (DAR8) |
HER2-ADC-03(DAR8) payload |
Undisclosed |
HER2-ADC-03(DAR8) linker |
[2] | |
HER2-ADC-04 (DAR8) |
HER2-ADC-04(DAR8) payload |
Undisclosed |
HER2-ADC-04(DAR8) linker |
[2] | |
HER2-ADC-05 (DAR8) |
HER2-ADC-05(DAR8) payload |
Undisclosed |
HER2-ADC-05(DAR8) linker |
[2] | |
HER2-ADC-06 (DAR8) |
HER2-ADC-06(DAR8) payload |
Undisclosed |
HER2-ADC-06(DAR8) linker |
[2] | |
HER2-ADC-07 (DAR8) |
HER2-ADC-07(DAR8) payload |
Undisclosed |
HER2-ADC-07(DAR8) linker |
[2] | |
HER2-ADC-08 (DAR8) |
HER2-ADC-08(DAR8) payload |
Undisclosed |
HER2-ADC-08(DAR8) linker |
[2] | |
HER2-ADC-09 (DAR8) |
HER2-ADC-09(DAR8) payload |
Undisclosed |
HER2-ADC-09(DAR8) linker |
[2] | |
HER2-ADC-10 (DAR8) |
HER2-ADC-10(DAR8) payload |
Undisclosed |
HER2-ADC-10(DAR8) linker |
[2] | |
WO2020063676A1 ADC-1 |
WO2020063676A1_ADC-1 payload |
Undisclosed |
WO2020063676A1_ADC-1 linker |
[53] | |
WO2020063676A1 ADC-2 |
WO2020063676A1_ADC-2 payload |
Undisclosed |
WO2020063676A1_ADC-2 linker |
[53] | |
WO2020063676A1 ADC-3 |
WO2020063676A1_ADC-3 payload |
Undisclosed |
WO2020063676A1_ADC-3 linker |
[53] | |
WO2020063676A1 ADC-4 |
WO2020063676A1_ADC-4 payload |
Undisclosed |
WO2020063676A1_ADC-4 linker |
[53] | |
WO2020063676A1 ADC-5 |
WO2020063676A1_ADC-5 payload |
Undisclosed |
WO2020063676A1_ADC-5 linker |
[53] | |
WO2020063676A1 ADC-6 |
WO2020063676A1_ADC-6 payload |
Undisclosed |
WO2020063676A1_ADC-6 linker |
[53] | |
WO2020063676A1 ADC-10 |
WO2020063676A1_ADC-10 payload |
Undisclosed |
WO2020063676A1_ADC-10 linker |
[53] | |
WO2020063676A1 ADC-11 |
WO2020063676A1_ADC-11 payload |
Undisclosed |
WO2020063676A1_ADC-11 linker |
[53] | |
WO2020063676A1 ADC-12 |
WO2020063676A1_ADC-12 payload |
Undisclosed |
WO2020063676A1_ADC-12 linker |
[53] | |
WO2020063676A1 ADC-13 |
WO2020063676A1_ADC-13 payload |
Undisclosed |
WO2020063676A1_ADC-13 linker |
[53] | |
WO2020063676A1 ADC-14 |
WO2020063676A1_ADC-14 payload |
Undisclosed |
WO2020063676A1_ADC-14 linker |
[53] | |
WO2020063676A1 ADC-15 |
WO2020063676A1_ADC-15 payload |
Undisclosed |
WO2020063676A1_ADC-15 linker |
[53] | |
WO2020063676A1 ADC-16 |
WO2020063676A1_ADC-16 payload |
Undisclosed |
WO2020063676A1_ADC-16 linker |
[53] | |
WO2020063676A1 ADC-17 |
WO2020063676A1_ADC-17 payload |
Undisclosed |
WO2020063676A1_ADC-17 linker |
[53] | |
WO2020063676A1 ADC-18 |
WO2020063676A1_ADC-18 payload |
Undisclosed |
WO2020063676A1_ADC-18 linker |
[53] | |
WO2020063676A1 ADC-19 |
WO2020063676A1_ADC-19 payload |
Undisclosed |
WO2020063676A1_ADC-19 linker |
[53] | |
WO2020063676A1 ADC-20 |
WO2020063676A1_ADC-20 payload |
Undisclosed |
WO2020063676A1_ADC-20 linker |
[53] | |
WO2020063676A1 ADC-21 |
WO2020063676A1_ADC-21 payload |
Undisclosed |
WO2020063676A1_ADC-21 linker |
[53] | |
WO2020063676A1 ADC-22 |
WO2020063676A1_ADC-22 payload |
Undisclosed |
WO2020063676A1_ADC-22 linker |
[53] | |
WO2020063676A1 ADC-23 |
WO2020063676A1_ADC-23 payload |
Undisclosed |
WO2020063676A1_ADC-23 linker |
[53] | |
WO2020063676A1 ADC-24 |
WO2020063676A1_ADC-24 payload |
Undisclosed |
WO2020063676A1_ADC-24 linker |
[53] | |
Trastuzumab-Compound (la) DAR 1.6 |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (la) DAR 1.6 linker |
[54] | |
Trastuzumab-Compound (la) DAR 8 |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (la) DAR 8 linker |
[54] | |
Trastuzumab-Compound (Ib) DAR1.5 |
NeoDegrader P3 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (Ib) DAR1.5 linker |
[54] | |
Trastuzumab-Compound (lc) |
NeoDegrader P4 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lc) linker |
[54] | |
Trastuzumab-Compound (lc) DAR 8 |
NeoDegrader P4 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lc) DAR 8 linker |
[54] | |
Trastuzumab-Compound (ld) DAR 1.6 |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (ld) DAR 1.6 linker |
[54] | |
Trastuzumab-Compound (le) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (le) linker |
[54] | |
Trastuzumab-Compound (lf) |
NeoDegrader P6 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lf) linker |
[54] | |
Trastuzumab-Compound (lg) |
NeoDegrader P2 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lg) linker |
[54] | |
Trastuzumab-Compound (lh) |
NeoDegrader P13 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lh) linker |
[54] | |
Trastuzumab-Compound (li) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (li) linker |
[54] | |
Trastuzumab-Compound (lk) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lk) linker |
[54] | |
Trastuzumab-Compound (ll) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (ll) linker |
[54] | |
Trastuzumab-Compound (lm) |
NeoDegrader P14 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lm) linker |
[54] | |
WO2017089895A1 ADC1 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC1 linker |
[104] | |
WO2017089895A1 ADC2 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC2 linker |
[104] | |
WO2017089895A1 ADC3 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC3 linker |
[104] | |
WO2017089895A1 ADC4 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC4 linker |
[104] | |
WO2017089895A1 ADC5 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC5 linker |
[104] | |
WO2017089895A1 ADC6 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC6 linker |
[104] | |
WO2017089895A1 ADC7 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC7 linker |
[104] | |
WO2017089895A1 ADC8 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC8 linker |
[104] | |
WO2017089895A1 ADC9 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC9 linker |
[104] | |
WO2017089895A1 ADC10 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC10 linker |
[104] | |
WO2017089895A1 ADC11 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC11 linker |
[104] | |
WO2017089895A1 ADC12 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC12 linker |
[104] | |
WO2017089895A1 ADC13 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC13 linker |
[104] | |
WO2017089895A1 ADC14 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC14 linker |
[104] | |
WO2017089895A1 ADC15 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC15 linker |
[104] | |
WO2017089895A1 ADC16 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC16 linker |
[104] | |
WO2017089895A1 ADC17 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC17 linker |
[104] | |
WO2017089895A1 ADC18 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC18 linker |
[104] | |
WO2017089895A1 ADC19 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC19 linker |
[104] | |
WO2017089895A1 ADC20 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC20 linker |
[104] | |
WO2017089895A1 ADC86 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC86 linker |
[104] | |
WO2017089895A1 ADC87 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC87 linker |
[104] | |
WO2017089895A1 ADC23 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC23 linker |
[104] | |
WO2017089895A1 ADC24 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC24 linker |
[104] | |
WO2017089895A1 ADC25 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC25 linker |
[104] | |
WO2017089895A1 ADC26 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC26 linker |
[104] | |
WO2017089895A1 ADC27 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC27 linker |
[104] | |
WO2017089895A1 ADC28 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC28 linker |
[104] | |
WO2017089895A1 ADC29 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC29 linker |
[104] | |
WO2017089895A1 ADC30 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC30 linker |
[104] | |
WO2017089895A1 ADC31 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC31 linker |
[104] | |
WO2017089895A1 ADC32 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC32 linker |
[104] | |
WO2017089895A1 ADC33 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC33 linker |
[104] | |
WO2017089895A1 ADC34 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC34 linker |
[104] | |
WO2017089895A1 ADC35 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC35 linker |
[104] | |
WO2017089895A1 ADC36 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC36 linker |
[104] | |
WO2017089895A1 ADC37 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC37 linker |
[104] | |
WO2017089895A1 ADC38 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC38 linker |
[104] | |
WO2017089895A1 ADC39 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC39 linker |
[104] | |
WO2017089895A1 ADC40 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC40 linker |
[104] | |
WO2017089895A1 ADC41 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC41 linker |
[104] | |
WO2017089895A1 ADC42 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC42 linker |
[104] | |
WO2017089895A1 ADC43 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC43 linker |
[104] | |
WO2017089895A1 ADC44 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC44 linker |
[104] | |
WO2017089895A1 ADC45 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC45 linker |
[104] | |
WO2017089895A1 ADC46 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC46 linker |
[104] | |
WO2017089895A1 ADC47 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC47 linker |
[104] | |
WO2017089895A1 ADC48 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC48 linker |
[104] | |
WO2017089895A1 ADC49 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC49 linker |
[104] | |
WO2017089895A1 ADC50 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC50 linker |
[104] | |
WO2017089895A1 ADC51 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC51 linker |
[104] | |
WO2017089895A1 ADC52 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC52 linker |
[104] | |
WO2017089895A1 ADC53 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC53 linker |
[104] | |
WO2017089895A1 ADC54 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC54 linker |
[104] | |
WO2017089895A1 ADC55 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC55 linker |
[104] | |
WO2017089895A1 ADC76 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC76 linker |
[104] | |
WO2017089895A1 ADC88 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC88 linker |
[104] | |
WO2017089895A1 ADC89 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC89 linker |
[104] | |
WO2017089895A1 ADC90 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC90 linker |
[104] | |
WO2017089895A1 ADC91 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC91 linker |
[104] | |
WO2017089895A1 ADC60 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC60 linker |
[104] | |
WO2017089895A1 ADC61 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC61 linker |
[104] | |
WO2017089895A1 ADC62 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC62 linker |
[104] | |
WO2017089895A1 ADC63 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089895A1_ADC63 linker |
[104] | |
WO2017089895A1 ADC77 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089895A1_ADC77 linker |
[104] | |
HER2-B Antibody-Compound (X) |
HER2-B Antibody-Compound (X) payload |
Undisclosed |
HER2-B Antibody-Compound (X) linker |
[38] | |
HER2-B Antibody-Compound (XI) |
HER2-B Antibody-Compound (XI) payload |
Undisclosed |
HER2-B Antibody-Compound (XI) linker |
[38] | |
HER2-B Antibody-Compound (XIV) |
HER2-B Antibody-Compound (XIV) payload |
Undisclosed |
HER2-B Antibody-Compound (XIV) linker |
[38] | |
HER2-B Antibody-Compound (XVIII) |
HER2-B Antibody-Compound (XVIII) payload |
Undisclosed |
HER2-B Antibody-Compound (XVIII) linker |
[38] | |
HER2-B Antibody-Compound (Ie) |
HER2-B Antibody-Compound (Ie) payload |
Undisclosed |
HER2-B Antibody-Compound (Ie) linker |
[38] | |
HER2-B Antibody-Compound (XIX) |
HER2-B Antibody-Compound (XIX) payload |
Undisclosed |
HER2-B Antibody-Compound (XIX) linker |
[38] | |
HER2-B Antibody-Compound (Ii) |
HER2-B Antibody-Compound (Ii) payload |
Undisclosed |
HER2-B Antibody-Compound (Ii) linker |
[38] | |
HER2-B Antibody-Compound (XLI) |
HER2-B Antibody-Compound (XLI) payload |
Undisclosed |
HER2-B Antibody-Compound (XLI) linker |
[38] | |
HER2-B Antibody-Compound (XVI) |
HER2-B Antibody-Compound (XIX) payload |
Undisclosed |
HER2-B Antibody-Compound (XIX) linker |
[38] | |
HER2-B Antibody-Compound (XL) |
HER2-B Antibody-Compound (XL) payload |
Undisclosed |
HER2-B Antibody-Compound (XL) linker |
[38] | |
HER2-B Antibody-Compound (XLII) |
HER2-B Antibody-Compound (XLII) payload |
Undisclosed |
HER2-B Antibody-Compound (XLII) linker |
[38] | |
Trastuzumab-Compound (XV) |
Trastuzumab-Compound (XV) payload |
Undisclosed |
Trastuzumab-Compound (XV) linker |
[38] | |
WO2013055987A1 Tmab-101 |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
WO2013055987A1_Tmab-101 linker |
[105] | |
WO2013055987A1 Tmab-102 |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
WO2013055987A1_Tmab-102 linker |
[105] | |
WO2013055987A1 Tmab-104 |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
WO2013055987A1_Tmab-104 linker |
[105] | |
WO2013055987A1 Tmab-110 |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
WO2013055987A1_Tmab-110 linker |
[105] | |
WO2014159981A2 ADC-110 |
WO2014159981A2_ADC-110 payload |
Undisclosed |
WO2014159981A2_ADC-110 linker |
[58] | |
WO2014159981A2 ADC-120 |
WO2014159981A2_ADC-120 payload |
Undisclosed |
WO2014159981A2_ADC-120 linker |
[58] | |
ADC-II-1 |
ADC-II-1 payload |
Undisclosed |
ADC-II-1 linker |
[106] | |
ADC-II-5 |
ADC-II-5 payload |
Undisclosed |
ADC-II-5 linker |
[106] | |
ADC-II-9 |
ADC-II-9 payload |
Undisclosed |
ADC-II-9 linker |
[106] | |
ADC-II-13 |
ADC-II-13 payload |
Undisclosed |
ADC-II-13 linker |
[106] | |
ADC-I-1 |
ADC-I-1 payload |
Undisclosed |
ADC-I-1 linker |
[106] | |
ADC-III-1 |
ADC-III-1 payload |
Undisclosed |
ADC-III-1 linker |
[106] | |
ADC-III-9 |
ADC-III-9 payload |
Undisclosed |
ADC-III-9 linker |
[106] | |
Trastuzumab-Gelonin |
Gelonin |
Ribosome (RB) |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB) |
[107] | |
Trastuzumab-Man-beta-1,4GlcNAc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc |
[108] | |
Trastuzumab-Glc-beta-1,4GlcNAc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Glc-beta-1,4GlcNAc |
[108] | |
Trastuzumab-Gal-beta-1,4GlcNAc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Gal-beta-1,4-GlcNAc |
[108] | |
Trastuzumab-MMAE conjugate DAR2 |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB |
[109] | |
Trastuzumab-MMAE conjugate DAR4 |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB |
[109] | |
Trastuzumab-MMAE conjugate DAR6 |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB |
[109] | |
Trastuzumab-MMAE conjugate DAR8 |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB |
[109] | |
Trastuzumab-MMAE conjugate DAR12 |
Monomethyl auristatin E |
Microtubule (MT) |
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB |
[109] | |
Trastuzumab imbotolimod |
Undisclosed |
Undisclosed |
Undisclosed |
[110] | |
Trastuzumab botidotin |
Undisclosed |
Undisclosed |
Undisclosed |
[111] | |
T-K-F (DAR 3.9) |
Monomethyl auristatin F |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[96] | |
Trastuzumab-G5-PNU |
PNU-159682 |
DNA topoisomerase 2-alpha (TOP2A) |
Gly5-FITC |
[85] | |
CRD-5500 antibody-drug conjugate |
CRD5500 |
Stimulator of interferon genes protein (STING1) |
Undisclosed |
[112] | |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Calicheamicin |
N-acetyl-gamma-calicheamicin |
Human Deoxyribonucleic acid (hDNA) |
BCN-HydraSpace-Val-Cit-PABC |
[80] | |
MYX2449 |
N-Myristolytransferase inhibitor (NMTi) |
Glycylpeptide N-tetradecanoyltransferase 1 (NMT1) |
Undisclosed |
[113] | |
Trastuzumab-L6 |
MF-6 |
DNA topoisomerase 1 (TOP1) |
Bridged PEG4-valine-alanine |
[114] | |
ADC Trast-7 |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[115] | |
ADC Trast-10 |
Monomethyl auristatin E |
Microtubule (MT) |
Bis-BCN-modified Val-Cit-PABC linker 10 |
[115] | |
ADC Trast-14 |
PBD dimer 3 |
Human Deoxyribonucleic acid (hDNA) |
Undisclosed |
[115] | |
ADC Trast-11 |
PBD dimer 3 |
Human Deoxyribonucleic acid (hDNA) |
Bis-BCN-modified Val-Cit-PABC linker 10 |
[115] | |
Trastuzumab-MCC-CpG conjugate |
Differentiated TLR-9 agonist (T-CpG) |
Toll-like receptor 9 (TLR9) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[116] | |
Trastuzumab-T1000-exatecan |
Exatecan |
DNA topoisomerase 1 (TOP1) |
Undisclosed |
[117] | |
Trastuzumab-NGM-PROTAC conjugate |
BRD4 PROTAC 3 |
Bromodomain-containing protein 4 (BRD4) |
NGM based linker |
[118] | |
Trastuzumab-iCME |
Membrane-impermable colchinolmethyl ether (iCME) cytotoxin |
Microtubule (MT) |
Pacific blue fluorophore-SH based linker |
[119] | |
IgG1 (trastuzumab)-vc-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[11] | |
Trastuzumab-DNA conjugate |
DNA mimics |
Human Deoxyribonucleic acid (hDNA) |
Undisclosed |
[120] | |
OHPAS ADC-1 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Ortho-hydroxy-protected aryl sulfate |
[121] | |
OHPAS ADC-2 |
SG2000 |
Human Deoxyribonucleic acid (hDNA) |
Ortho-hydroxy-protected aryl sulfate |
[121] | |
OHPAS ADC-3 |
seco-CBI-indole |
Human Deoxyribonucleic acid (hDNA) |
Ortho-hydroxy-protected aryl sulfate |
[121] | |
OHPAS ADC-4 |
CBI-dimer-beta-Gal |
Human Deoxyribonucleic acid (hDNA) |
Ortho-hydroxy-protected aryl sulfate |
[121] | |
Trastuzumab/nab-paclitaxel |
Paclitaxel |
Microtubule (MT) |
Undisclosed |
[122] | |
Docetaxel-trastuzumab |
Docetaxel |
Microtubule (MT) |
Undisclosed |
[123] | |
Trastuzumab-PC4AP-DOX |
Doxorubicin |
DNA topoisomerase 2-alpha (TOP2A) |
Photocaged C4AP |
[124] | |
T (Anti-HER2)-30.2060 |
Amanitin 30.206 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[23] | |
T (Anti-HER2)-30.2867 |
Amanitin 30.2867 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Maleimido-caproyl |
[23] | |
Trastuzumab-Compound (lj) |
NeoDegrader P1 |
Protein cereblon (CRBN) |
Trastuzumab-Compound (lj) linker |
[54] | |
WO2017089895A1 ADC21 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089895A1_ADC21 linker |
[104] | |
WO2017089895A1 ADC22 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089895A1_ADC22 linker |
[104] | |
WO2017089895A1 ADC56 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089895A1_ADC56 linker |
[104] | |
WO2017089895A1 ADC57 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089895A1_ADC57 linker |
[104] | |
WO2017089895A1 ADC58 |
Alpha-amanitin+Monomethyl auristatin F |
Undisclosed |
WO2017089895A1_ADC58 linker |
[104] | |
WO2017089895A1 ADC59 |
Alpha-amanitin+Monomethyl auristatin F |
Undisclosed |
WO2017089895A1_ADC59 linker |
[104] | |
HER2-B Antibody-Compound (XLIII) |
HER2-B Antibody-Compound (XLIII) payload |
Undisclosed |
HER2-B Antibody-Compound (XLIII) linker |
[38] | |
WO2022078260A1 ADC-1 |
Ln-D9 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-1 linker |
[125] | |
WO2022078260A1 ADC-2 |
Ln-D1 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-2 linker |
[125] | |
WO2022078260A1 ADC-3 |
Ln-D2 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-3 linker |
[125] | |
WO2022078260A1 ADC-4 |
Ln-D4 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-4 linker |
[125] | |
WO2022078260A1 ADC-5 |
Ln-D5 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-5 linker |
[125] | |
WO2022078260A1 ADC-6 |
Ln-D6 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-6 linker |
[125] | |
WO2022078260A1 ADC-7 |
Ln-D7 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-7 linker |
[125] | |
WO2022078260A1 ADC-8 |
Ln-D8 |
DNA topoisomerase 1 (TOP1) |
WO2022078260A1_ADC-8 linker |
[125] | |
WO2021249228A1 ADC-1 |
WO2021249228A1_ADC-1 payload |
Undisclosed |
WO2021249228A1_ADC-1 linker |
[126] | |
WO2021249228A1 ADC-2 |
WO2021249228A1_ADC-2 payload |
Undisclosed |
WO2021249228A1_ADC-2 linker |
[126] | |
WO2021249228A1 ADC-3 |
WO2021249228A1_ADC-3 payload |
Undisclosed |
WO2021249228A1_ADC-3 linker |
[126] | |
WO2021249228A1 ADC-4 |
WO2021249228A1_ADC-4 payload |
Undisclosed |
WO2021249228A1_ADC-4 linker |
[126] | |
WO2021249228A1 ADC-5 |
WO2021249228A1_ADC-5 payload |
Undisclosed |
WO2021249228A1_ADC-5 linker |
[126] | |
WO2021249228A1 ADC-6 |
WO2021249228A1_ADC-6 payload |
Undisclosed |
WO2021249228A1_ADC-6 linker |
[126] | |
WO2021249228A1 ADC-7 |
WO2021249228A1_ADC-7 payload |
Undisclosed |
WO2021249228A1_ADC-7 linker |
[126] | |
WO2021249228A1 ADC-8 |
WO2021249228A1_ADC-8 payload |
Undisclosed |
WO2021249228A1_ADC-8 linker |
[126] | |
WO2021249228A1 ADC-9 |
WO2021249228A1_ADC-9 payload |
Undisclosed |
WO2021249228A1_ADC-9 linker |
[126] | |
WO2021249228A1 ADC-10 |
WO2021249228A1_ADC-10 payload |
Undisclosed |
WO2021249228A1_ADC-10 linker |
[126] | |
WO2021249228A1 ADC-11 |
WO2021249228A1_ADC-11 payload |
Undisclosed |
WO2021249228A1_ADC-11 linker |
[126] | |
WO2021249228A1 ADC-12 |
WO2021249228A1_ADC-12 payload |
Undisclosed |
WO2021249228A1_ADC-12 linker |
[126] | |
WO2021249228A1 ADC-13 |
WO2021249228A1_ADC-13 payload |
Undisclosed |
WO2021249228A1_ADC-13 linker |
[126] | |
WO2021249228A1 ADC-14 |
WO2021249228A1_ADC-14 payload |
Undisclosed |
WO2021249228A1_ADC-14 linker |
[126] | |
WO2021249228A1 ADC-15 |
WO2021249228A1_ADC-15 payload |
Undisclosed |
WO2021249228A1_ADC-15 linker |
[126] | |
WO2021249228A1 ADC-16 |
WO2021249228A1_ADC-16 payload |
Undisclosed |
WO2021249228A1_ADC-16 linker |
[126] | |
WO2021249228A1 ADC-17 |
WO2021249228A1_ADC-17 payload |
Undisclosed |
WO2021249228A1_ADC-17 linker |
[126] | |
WO2021249228A1 ADC-18 |
WO2021249228A1_ADC-18 payload |
Undisclosed |
WO2021249228A1_ADC-18 linker |
[126] | |
WO2021249228A1 ADC-19 |
WO2021249228A1_ADC-19 payload |
Undisclosed |
WO2021249228A1_ADC-19 linker |
[126] | |
WO2021249228A1 ADC-20 |
WO2021249228A1_ADC-20 payload |
Undisclosed |
WO2021249228A1_ADC-20 linker |
[126] | |
WO2021249228A1 ADC-21 |
WO2021249228A1_ADC-21 payload |
Undisclosed |
WO2021249228A1_ADC-21 linker |
[126] | |
WO2021249228A1 ADC-22 |
WO2021249228A1_ADC-22 payload |
Undisclosed |
WO2021249228A1_ADC-22 linker |
[126] | |
WO2021249228A1 ADC-23 |
WO2021249228A1_ADC-23 payload |
Undisclosed |
WO2021249228A1_ADC-23 linker |
[126] | |
WO2021249228A1 ADC-24 |
WO2021249228A1_ADC-24 payload |
Undisclosed |
WO2021249228A1_ADC-24 linker |
[126] | |
WO2021249228A1 ADC-25 |
WO2021249228A1_ADC-25 payload |
Undisclosed |
WO2021249228A1_ADC-25 linker |
[126] | |
WO2021249228A1 ADC-26 |
WO2021249228A1_ADC-26 payload |
Undisclosed |
WO2021249228A1_ADC-26 linker |
[126] | |
WO2021249228A1 ADC-27 |
WO2021249228A1_ADC-27 payload |
Undisclosed |
WO2021249228A1_ADC-27 linker |
[126] | |
WO2021249228A1 ADC-28 |
WO2021249228A1_ADC-28 payload |
Undisclosed |
WO2021249228A1_ADC-28 linker |
[126] | |
WO2021249228A1 ADC-29 |
WO2021249228A1_ADC-29 payload |
Undisclosed |
WO2021249228A1_ADC-29 linker |
[126] | |
WO2021249228A1 ADC-30 |
WO2021249228A1_ADC-30 payload |
Undisclosed |
WO2021249228A1_ADC-30 linker |
[126] | |
WO2021249228A1 ADC-31 |
WO2021249228A1_ADC-31 payload |
Undisclosed |
WO2021249228A1_ADC-31 linker |
[126] | |
WO2021249228A1 ADC-32 |
WO2021249228A1_ADC-32 payload |
Undisclosed |
WO2021249228A1_ADC-32 linker |
[126] | |
WO2021249228A1 ADC-33 |
WO2021249228A1_ADC-33 payload |
Undisclosed |
WO2021249228A1_ADC-33 linker |
[126] | |
WO2021249228A1 ADC-34 |
WO2021249228A1_ADC-34 payload |
Undisclosed |
WO2021249228A1_ADC-34 linker |
[126] | |
WO2021249228A1 ADC-35 |
WO2021249228A1_ADC-35 payload |
Undisclosed |
WO2021249228A1_ADC-35 linker |
[126] | |
WO2021249228A1 ADC-36 |
WO2021249228A1_ADC-36 payload |
Undisclosed |
WO2021249228A1_ADC-36 linker |
[126] | |
WO2021249228A1 ADC-37 |
WO2021249228A1_ADC-37 payload |
Undisclosed |
WO2021249228A1_ADC-37 linker |
[126] | |
WO2021249228A1 ADC-38 |
WO2021249228A1_ADC-38 payload |
Undisclosed |
WO2021249228A1_ADC-38 linker |
[126] | |
WO2021249228A1 ADC-39 |
WO2021249228A1_ADC-39 payload |
Undisclosed |
WO2021249228A1_ADC-39 linker |
[126] | |
WO2021249228A1 ADC-40 |
WO2021249228A1_ADC-40 payload |
Undisclosed |
WO2021249228A1_ADC-40 linker |
[126] | |
WO2021249228A1 ADC-41 |
WO2021249228A1_ADC-41 payload |
Undisclosed |
WO2021249228A1_ADC-41 linker |
[126] | |
WO2021249228A1 ADC-42 |
WO2021249228A1_ADC-42 payload |
Undisclosed |
WO2021249228A1_ADC-42 linker |
[126] | |
WO2021249228A1 ADC-43 |
WO2021249228A1_ADC-43 payload |
Undisclosed |
WO2021249228A1_ADC-43 linker |
[126] | |
WO2021249228A1 ADC-44 |
WO2021249228A1_ADC-44 payload |
Undisclosed |
WO2021249228A1_ADC-44 linker |
[126] | |
WO2021249228A1 ADC-45 |
WO2021249228A1_ADC-45 payload |
Undisclosed |
WO2021249228A1_ADC-45 linker |
[126] | |
WO2021249228A1 ADC-46 |
WO2021249228A1_ADC-46 payload |
Undisclosed |
WO2021249228A1_ADC-46 linker |
[126] | |
WO2021249228A1 ADC-47 |
WO2021249228A1_ADC-47 payload |
Undisclosed |
WO2021249228A1_ADC-47 linker |
[126] | |
WO2021249228A1 ADC-48 |
WO2021249228A1_ADC-48 payload |
Undisclosed |
WO2021249228A1_ADC-48 linker |
[126] | |
WO2021249228A1 ADC-49 |
WO2021249228A1_ADC-49 payload |
Undisclosed |
WO2021249228A1_ADC-49 linker |
[126] | |
WO2021249228A1 ADC-50 |
WO2021249228A1_ADC-50 payload |
Undisclosed |
WO2021249228A1_ADC-50 linker |
[126] | |
WO2021249228A1 ADC-51 |
WO2021249228A1_ADC-51 payload |
Undisclosed |
WO2021249228A1_ADC-51 linker |
[126] | |
WO2021249228A1 ADC-52 |
WO2021249228A1_ADC-52 payload |
Undisclosed |
WO2021249228A1_ADC-52 linker |
[126] | |
WO2021249228A1 ADC-53 |
WO2021249228A1_ADC-53 payload |
Undisclosed |
WO2021249228A1_ADC-53 linker |
[126] | |
WO2021249228A1 ADC-54 |
WO2021249228A1_ADC-54 payload |
Undisclosed |
WO2021249228A1_ADC-54 linker |
[126] | |
WO2021249228A1 ADC-55 |
WO2021249228A1_ADC-55 payload |
Undisclosed |
WO2021249228A1_ADC-55 linker |
[126] | |
WO2021249228A1 ADC-56 |
WO2021249228A1_ADC-56 payload |
Undisclosed |
WO2021249228A1_ADC-56 linker |
[126] | |
WO2021249228A1 ADC-57 |
WO2021249228A1_ADC-57 payload |
Undisclosed |
WO2021249228A1_ADC-57 linker |
[126] | |
WO2021249228A1 ADC-58 |
WO2021249228A1_ADC-58 payload |
Undisclosed |
WO2021249228A1_ADC-58 linker |
[126] | |
WO2021249228A1 ADC-59 |
WO2021249228A1_ADC-59 payload |
Undisclosed |
WO2021249228A1_ADC-59 linker |
[126] | |
WO2021249228A1 ADC-60 |
WO2021249228A1_ADC-60 payload |
Undisclosed |
WO2021249228A1_ADC-60 linker |
[126] | |
WO2021249228A1 ADC-61 |
WO2021249228A1_ADC-61 payload |
Undisclosed |
WO2021249228A1_ADC-61 linker |
[126] | |
WO2022228495A1 ADC-67 |
WO2022228495A1 ADC-67 payload |
Undisclosed |
WO2022228495A1 ADC-67 linker |
[37] | |
WO2022228495A1 ADC-68 |
WO2022228495A1 ADC-68 payload |
Undisclosed |
WO2022228495A1 ADC-68 linker |
[37] | |
WO2022228495A1 ADC-69 |
WO2022228495A1 ADC-69 payload |
Undisclosed |
WO2022228495A1 ADC-69 linker |
[37] | |
WO2022228495A1 ADC-70 |
WO2022228495A1 ADC-70 payload |
Undisclosed |
WO2022228495A1 ADC-70 linker |
[37] | |
WO2022228495A1 ADC-71 |
WO2022228495A1 ADC-71 payload |
Undisclosed |
WO2022228495A1 ADC-71 linker |
[37] | |
WO2022228495A1 ADC-74 |
WO2022228495A1 ADC-74 payload |
Undisclosed |
WO2022228495A1 ADC-74 linker |
[37] | |
WO2022228495A1 ADC-75 |
WO2022228495A1 ADC-75 payload |
Undisclosed |
WO2022228495A1 ADC-75 linker |
[37] | |
HER2-MMAU ADC |
Glucuronyl-monomethyl-auristatin E (MMAU) |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[127] | |
PF-06888667 |
SW-163D |
Human Deoxyribonucleic acid (hDNA) |
AcLys-Val-Cit-PABC-DMAE |
[128] | |
TTZ-1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
DSPh-Val-Ala-PABC |
[129] | |
TTZ-2-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
DSPh-Val-Cit-PABC |
[129] | |
TTZ-3-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
DSPh-PEG12-Val-Ala-PABC |
[129] | |
TTZ-4-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
DSPh-PEG12-Val-Cit-PABC |
[129] | |
Trastuzumab-DVP-linker-MMAE 1 |
Monomethyl auristatin E |
Microtubule (MT) |
DVP-based linker 1f |
[130] | |
Trastuzumab-Val-Cit linker-MMAE 2 |
Monomethyl auristatin E |
Microtubule (MT) |
Val-Cit linker 2e |
[130] | |
Trastuzumab-DVP-linker-MMAE 3 |
Monomethyl auristatin E |
Microtubule (MT) |
DVP-based linker 3 |
[130] | |
Trastuzumab-DVP-linker-MMAE 4 |
Monomethyl auristatin E |
Microtubule (MT) |
DVP-based linker 4 |
[130] | |
Trastuzumab-Me-PRX conjugate |
Methylated-beta-Cyclodextrin/Pluronic P103-based polyrotaxane (Me-PRX) |
Undisclosed |
Phenyl maleimide PEG2 |
[131] | |
T-PBA |
PBD-based payload 37b3 |
Human Deoxyribonucleic acid (hDNA) |
Mc-Val-Ala |
[132] | |
HER2-acetal-ADC 11 |
Monomethyl auristatin F |
Microtubule (MT) |
Clravable-acetal based linker 11 |
[133] | |
HER2-acetal-ADC 12 |
Monomethyl auristatin F |
Microtubule (MT) |
Clravable-TAMRA-acetal based linker 12 |
[133] | |
HER2-azide-alkyne MMAE conjugate |
Monomethyl auristatin E |
Microtubule (MT) |
Azide-alkyne based linker 10a |
[134] | |
HER2-cyclopropene-tetrazine MMAE conjugate |
Monomethyl auristatin E |
Microtubule (MT) |
Cyclopropene-tetrazine based linker 10b |
[134] | |
HER2-norbornene-tetrazine MMAE conjugate |
Monomethyl auristatin E |
Microtubule (MT) |
Norbornene-tetrazine based linker 10c |
[134] | |
T-FcBP-DM1 |
Mertansine DM1 |
Microtubule (MT) |
N-terminal norbornene group pFcBP linker |
[135] | |
T-D8-1508 |
AZ-1508 |
Microtubule (MT) |
Cysteine D8 |
[136] | |
T-D6-1508 |
AZ-1508 |
Microtubule (MT) |
Cysteine D6 |
[136] | |
T-D4-1508 |
AZ-1508 |
Microtubule (MT) |
Cysteine D4 |
[136] | |
T-D2-1508 |
AZ-1508 |
Microtubule (MT) |
Cysteine D2 |
[136] | |
HER2 ADC-18 |
Monomethyl auristatin E |
Microtubule (MT) |
Vinylsulfonamide based linker 15 |
[137] | |
HER2 ADC-19 |
Monomethyl auristatin E |
Microtubule (MT) |
Vinylsulfonamide based linker 16 |
[137] | |
HER2 ADC-20 |
Monomethyl auristatin E |
Microtubule (MT) |
Vinylsulfonamide based linker 17 |
[137] | |
T-DM1-IR700 |
Mertansine DM1 plus IRDye700DX |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[138] | |
HER2-gsADC-46 |
Monomethyl auristatin E |
Microtubule (MT) |
ThioPz linker 6a |
[27] | |
HER2-gsADC-47 |
Monomethyl auristatin E |
Microtubule (MT) |
Hydroxylamine derivative 6c |
[27] | |
HER2-gsADC-48 |
Monomethyl auristatin E |
Microtubule (MT) |
2-Aminobenzamide oxime |
[27] | |
HER2-gsADC-49 |
Monomethyl auristatin E |
Microtubule (MT) |
Azadibenzocylooctyne-amine derivative 6d |
[27] | |
HER2-gsADC-50 |
Monomethyl auristatin E |
Microtubule (MT) |
2-Aminobenzamidoxime without core-fucosylation |
[27] | |
T-DM1-2.6 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[27] | |
Trastuzumab-amanitin 1 |
Beta-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-Amanitin1 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 3 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 3 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 4 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 4 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 7 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 7 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 10 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 10 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 11 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 11 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 14 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 14 linker |
[139] | |
Trastuzumab-alpha-amanitin conjugate 15 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-alpha-amanitin conjugate 15 linker |
[139] | |
Trastuzumab-amanitin 3 |
Beta-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-Amanitin3 linker |
[139] | |
Trastuzumab-amanitin 4 |
Beta-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Trastuzumab-Amanitin4 linker |
[139] | |
Her-30.0643 |
HDP 30.0643 |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Her-30.0643 linker |
[140] | |
Her-30.1033 |
HDP 30.1033 |
Undisclosed |
Her-30.1033 linker |
[140] | |
Her-30.1036 |
HDP 30.1036 |
Undisclosed |
Her-30.1036 linker |
[140] | |
Her-30.1165 |
HDP 30.1165 |
Undisclosed |
Her-30.1165 linker |
[140] | |
Her-30.0132 |
HDP 30.0132 |
Undisclosed |
Her-30.0132 linker |
[140] | |
Her-30.0134 |
HDP 30.0134 |
Undisclosed |
Her-30.0134 linker |
[140] | |
Her-30.0741 |
HDP 30.0741 |
Undisclosed |
Her-30.0741 linker |
[140] | |
Her-30.0743 |
HDP 30.0743 |
Undisclosed |
Her-30.0743 linker |
[140] | |
Trastuzumab-E-13 |
Trastuzumab-E-13 payload |
Undisclosed |
Trastuzumab-E-13 linker |
[141] | |
Trastuzumab-G-13 |
Trastuzumab-G-13 payload |
Undisclosed |
Trastuzumab-G-13 linker |
[141] | |
Trastuzumab-E-11 |
Trastuzumab-E-11 payload |
Undisclosed |
Trastuzumab-E-11 linker |
[141] | |
Trastuzumab-E-12 |
Trastuzumab-E-12 payload |
Undisclosed |
Trastuzumab-E-12 payload |
[141] | |
Trastuzumab-G-12 |
Trastuzumab-G-12 payload |
Undisclosed |
Trastuzumab-G-12E-11 |
[141] | |
Trastuzumab-F-13 |
Trastuzumab-F-13 payload |
Undisclosed |
Trastuzumab-F-13E-12 |
[141] | |
Trastuzumab-E-15 |
Trastuzumab-E-15 payload |
Undisclosed |
Trastuzumab-E-15G-12 |
[141] | |
Trastuzumab-G-15 |
Trastuzumab-G-15 payload |
Undisclosed |
Trastuzumab-G-15F-13 |
[141] | |
Trastuzumab-F-61 |
Trastuzumab-F-61 payload |
Undisclosed |
Trastuzumab-F-61E-15 |
[141] | |
Trastuzumab-F-62 |
Trastuzumab-F-62 payload |
Undisclosed |
Trastuzumab-F-62G-15 |
[141] | |
Trastuzumab-F-63 |
Trastuzumab-F-63 payload |
Undisclosed |
Trastuzumab-F-63F-61 |
[141] | |
WO2017089890A1 ADC1 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC1 linker |
[142] | |
WO2017089890A1 ADC2 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC2 linker |
[142] | |
WO2017089890A1 ADC3 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC3 linker |
[142] | |
WO2017089890A1 ADC4 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC4 linker |
[142] | |
WO2017089890A1 ADC5 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC5 linker |
[142] | |
WO2017089890A1 ADC6 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC6 linker |
[142] | |
WO2017089890A1 ADC7 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC7 linker |
[142] | |
WO2017089890A1 ADC8 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC8 linker |
[142] | |
WO2017089890A1 ADC9 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC9 linker |
[142] | |
WO2017089890A1 ADC10 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC10 linker |
[142] | |
WO2017089890A1 ADC11 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC11 linker |
[142] | |
WO2017089890A1 ADC12 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC12 linker |
[142] | |
WO2017089890A1 ADC13 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC13 linker |
[142] | |
WO2017089890A1 ADC14 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC14 linker |
[142] | |
WO2017089890A1 ADC15 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC15 linker |
[142] | |
WO2017089890A1 ADC16 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC16 linker |
[142] | |
WO2017089890A1 ADC17 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC17 linker |
[142] | |
WO2017089890A1 ADC18 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC18 linker |
[142] | |
WO2017089890A1 ADC19 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC19 linker |
[142] | |
WO2017089890A1 ADC20 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC20 linker |
[142] | |
WO2017089890A1 ADC86 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC86 linker |
[142] | |
WO2017089890A1 ADC87 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC87 linker |
[142] | |
WO2017089890A1 ADC23 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC23 linker |
[142] | |
WO2017089890A1 ADC24 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC24 linker |
[142] | |
WO2017089890A1 ADC25 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC25 linker |
[142] | |
WO2017089890A1 ADC26 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC26 linker |
[142] | |
WO2017089890A1 ADC27 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC27 linker |
[142] | |
WO2017089890A1 ADC28 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC28 linker |
[142] | |
WO2017089890A1 ADC29 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC29 linker |
[142] | |
WO2017089890A1 ADC30 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC30 linker |
[142] | |
WO2017089890A1 ADC31 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC31 linker |
[142] | |
WO2017089890A1 ADC32 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC32 linker |
[142] | |
WO2017089890A1 ADC33 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC33 linker |
[142] | |
WO2017089890A1 ADC34 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC34 linker |
[142] | |
WO2017089890A1 ADC35 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC35 linker |
[142] | |
WO2017089890A1 ADC36 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC36 linker |
[142] | |
WO2017089890A1 ADC37 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC37 linker |
[142] | |
WO2017089890A1 ADC38 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC38 linker |
[142] | |
WO2017089890A1 ADC39 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC39 linker |
[142] | |
WO2017089890A1 ADC40 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC40 linker |
[142] | |
WO2017089890A1 ADC41 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC41 linker |
[142] | |
WO2017089890A1 ADC42 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC42 linker |
[142] | |
WO2017089890A1 ADC43 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC43 linker |
[142] | |
WO2017089890A1 ADC44 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC44 linker |
[142] | |
WO2017089890A1 ADC45 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC45 linker |
[142] | |
WO2017089890A1 ADC46 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC46 linker |
[142] | |
WO2017089890A1 ADC47 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC47 linker |
[142] | |
WO2017089890A1 ADC48 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC48 linker |
[142] | |
WO2017089890A1 ADC49 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC49 linker |
[142] | |
WO2017089890A1 ADC50 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC50 linker |
[142] | |
WO2017089890A1 ADC51 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC51 linker |
[142] | |
WO2017089890A1 ADC52 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC52 linker |
[142] | |
WO2017089890A1 ADC53 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC53 linker |
[142] | |
WO2017089890A1 ADC54 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC54 linker |
[142] | |
WO2017089890A1 ADC55 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC55 linker |
[142] | |
WO2017089890A1 ADC76 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC76 linker |
[142] | |
WO2017089890A1 ADC88 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC88 linker |
[142] | |
WO2017089890A1 ADC89 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC89 linker |
[142] | |
WO2017089890A1 ADC90 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC90 linker |
[142] | |
WO2017089890A1 ADC91 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC91 linker |
[142] | |
WO2017089890A1 ADC60 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC60 linker |
[142] | |
WO2017089890A1 ADC61 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC61 linker |
[142] | |
WO2017089890A1 ADC62 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC62 linker |
[142] | |
WO2017089890A1 ADC63 |
Monomethyl auristatin E |
Microtubule (MT) |
WO2017089890A1_ADC63 linker |
[142] | |
WO2017089890A1 ADC77 |
Monomethyl auristatin F |
Microtubule (MT) |
WO2017089890A1_ADC77 linker |
[142] | |
WO2017089890A1 ADC21 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089890A1_ADC21 linker |
[142] | |
WO2017089890A1 ADC22 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089890A1_ADC22 linker |
[142] | |
WO2017089890A1 ADC56 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089890A1_ADC56 linker |
[142] | |
WO2017089890A1 ADC57 |
Alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
WO2017089890A1_ADC57 linker |
[142] | |
WO2017089890A1 ADC58 |
Alpha-amanitin+Monomethyl auristatin E |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT) |
WO2017089890A1_ADC58 linker |
[142] | |
WO2017089890A1 ADC59 |
Alpha-amanitin+Monomethyl auristatin E |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT) |
WO2017089890A1_ADC59 linker |
[142] | |
WO2017089890A1 ADC78 |
Alpha-amanitin+Monomethyl auristatin E |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT) |
WO2017089890A1_ADC78 linker |
[142] | |
WO2018098269A2 conjugate 25 |
WO2018098269A2_conjugate 25 payload |
Undisclosed |
WO2018098269A2_conjugate 25 linker |
[143] | |
WO2018098269A2 conjugate 28 |
WO2018098269A2_conjugate 28 payload |
Undisclosed |
WO2018098269A2_conjugate 28 linker |
[143] | |
WO2018098269A2 conjugate 31A |
WO2018098269A2_conjugate 31A payload |
Undisclosed |
WO2018098269A2_conjugate 31A linker |
[143] | |
WO2018098269A2 conjugate 34A |
WO2018098269A2_conjugate 34A payload |
Undisclosed |
WO2018098269A2_conjugate 34A linker |
[143] | |
WO2018098269A2 conjugate 43A |
WO2018098269A2_conjugate 43A payload |
Undisclosed |
WO2018098269A2_conjugate 43A linker |
[143] | |
WO2018098269A2 conjugate 46A |
WO2018098269A2_conjugate 46A payload |
Undisclosed |
WO2018098269A2_conjugate 46A linker |
[143] | |
WO2018098269A2 conjugate 48 |
WO2018098269A2_conjugate 48 payload |
Undisclosed |
WO2018098269A2_conjugate 48 linker |
[143] | |
WO2018098269A2 conjugate 50 |
WO2018098269A2_conjugate 50 payload |
Undisclosed |
WO2018098269A2_conjugate 50 linker |
[143] | |
WO2018098269A2 conjugate 52 |
WO2018098269A2_conjugate 52 payload |
Undisclosed |
WO2018098269A2_conjugate 52 linker |
[143] | |
WO2018098269A2 conjugate 67 |
WO2018098269A2_conjugate 67 payload |
Undisclosed |
WO2018098269A2_conjugate 67 linker |
[143] | |
WO2018098269A2 conjugate 68 |
WO2018098269A2_conjugate 68 payload |
Undisclosed |
WO2018098269A2_conjugate 68 linker |
[143] | |
WO2018098269A2 conjugate 46B |
WO2018098269A2_conjugate 46B payload |
Undisclosed |
WO2018098269A2_conjugate 46B linker |
[143] | |
WO2018098269A2 conjugate 43B |
WO2018098269A2_conjugate 43B payload |
Undisclosed |
WO2018098269A2_conjugate 43B linker |
[143] | |
WO2018098269A2 conjugate 34B |
WO2018098269A2_conjugate 34B payload |
Undisclosed |
WO2018098269A2_conjugate 34B linker |
[143] | |
WO2018098269A2 conjugate 31B |
WO2018098269A2_conjugate 31B payload |
Undisclosed |
WO2018098269A2_conjugate 31B linker |
[143] | |
WO2015004400A1 ADC-1 |
WO2015004400A1 ADC-1 payload |
Undisclosed |
WO2015004400A1 ADC-1 linker |
[144] | |
WO2015004400A1 ADC-2 |
WO2015004400A1 ADC-2 payload |
Undisclosed |
WO2015004400A1 ADC-2 linker |
[144] | |
WO2015004400A1 ADC-3 |
WO2015004400A1 ADC-3 payload |
Undisclosed |
WO2015004400A1 ADC-3 linker |
[144] | |
WO2015004400A1 ADC-4 |
WO2015004400A1 ADC-4 payload |
Undisclosed |
WO2015004400A1 ADC-4 linker |
[144] | |
WO2015004400A1 ADC-5 |
WO2015004400A1 ADC-5 payload |
Undisclosed |
WO2015004400A1 ADC-5 linker |
[144] | |
WO2015004400A1 ADC-6 |
WO2015004400A1 ADC-6 payload |
Undisclosed |
WO2015004400A1 ADC-6 linker |
[144] | |
WO2015004400A1 ADC-7 |
WO2015004400A1 ADC-7 payload |
Undisclosed |
WO2015004400A1 ADC-7 linker |
[144] | |
WO2015004400A1 ADC-8 |
WO2015004400A1 ADC-8 payload |
Undisclosed |
WO2015004400A1 ADC-8 linker |
[144] | |
Trastuzumab-Compound 9 |
Mertansine DM1 |
Microtubule (MT) |
Trastuzumab-Compound 9 linker |
[15] | |
Trastuzumab-Compound 17 |
Mertansine DM4 |
Microtubule (MT) |
Trastuzumab-Compound 17 linker |
[15] | |
Trastuzumab-Compound 25 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 25 linker |
[15] | |
Trastuzumab-Compound 31 |
Auristatin 0101 |
Microtubule (MT) |
Trastuzumab-Compound 31 linker |
[15] | |
Trastuzumab-Compound 36 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 36 linker |
[15] | |
Trastuzumab-Compound 43 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Trastuzumab-Compound 43 linker |
[15] | |
Trastuzumab-Compound 49 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Trastuzumab-Compound 49 linker |
[15] | |
Trastuzumab-Compound 55 |
Mertansine DM1 |
Microtubule (MT) |
Trastuzumab-Compound 55 linker |
[15] | |
Trastuzumab-Compound 59 |
Mertansine DM4 |
Microtubule (MT) |
Trastuzumab-Compound 59 linker |
[15] | |
Trastuzumab-Compound 64 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 64 linker |
[15] | |
Trastuzumab-Compound 69 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 69 linker |
[15] | |
Trastuzumab-Compound 74 |
PBD dimer |
Human Deoxyribonucleic acid (hDNA) |
Trastuzumab-Compound 74 linker |
[15] | |
Trastuzumab-Compound 75 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 75 linker |
[15] | |
Trastuzumab-Compound 76 |
Monomethyl auristatin E |
Microtubule (MT) |
Trastuzumab-Compound 76 linker |
[15] | |
Trastuzumab-Compound 77 |
Mertansine DM1 |
Microtubule (MT) |
Trastuzumab-Compound 77 linker |
[15] | |
Trastuzumab-Compound 78 |
Auristatin 0101 |
Microtubule (MT) |
Trastuzumab-Compound 78 linker |
[15] | |
Trastuzumab-Compound 79 |
Auristatin 0101 |
Microtubule (MT) |
Trastuzumab-Compound 79 linker |
[15] | |
Trastuzumab-Compound 80 |
Mertansine DM4 |
Microtubule (MT) |
Trastuzumab-Compound 80 linker |
[15] | |
CN114917361A ADC-2 |
CN114917361A ADC-2 payload |
Undisclosed |
CN114917361A ADC-2 linker |
[145] | |
CN114917361A ADC-7 |
CN114917361A ADC-7 payload |
Undisclosed |
CN114917361A ADC-7 linker |
[145] | |
CN114917361A ADC-14 |
CN114917361A ADC-14 payload |
Undisclosed |
CN114917361A ADC-14 linker |
[145] | |
CN114917361A ADC-17 |
CN114917361A ADC-17 payload |
Undisclosed |
CN114917361A ADC-17 linker |
[145] | |
CN114917361A ADC-22 |
CN114917361A ADC-22 payload |
Undisclosed |
CN114917361A ADC-22 linker |
[145] | |
CN114917361A ADC-28 |
CN114917361A ADC-28 payload |
Undisclosed |
CN114917361A ADC-28 linker |
[145] | |
CN114917361A ADC-31 |
CN114917361A ADC-31 payload |
Undisclosed |
CN114917361A ADC-31 linker |
[145] | |
CN114917361A ADC-34 |
CN114917361A ADC-34 payload |
Undisclosed |
CN114917361A ADC-34 linker |
[145] | |
CN114917361A ADC-37 |
CN114917361A ADC-37 payload |
Undisclosed |
CN114917361A ADC-37 linker |
[145] | |
CN114917361A ADC-42 |
CN114917361A ADC-42 payload |
Undisclosed |
CN114917361A ADC-42 linker |
[145] | |
CN114917361A ADC-45 |
CN114917361A ADC-45 payload |
Undisclosed |
CN114917361A ADC-45 linker |
[145] | |
CN114917361A ADC-48 |
CN114917361A ADC-48 payload |
Undisclosed |
CN114917361A ADC-48 linker |
[145] | |
CN114917361A ADC-51 |
CN114917361A ADC-51 payload |
Undisclosed |
CN114917361A ADC-51 linker |
[145] | |
CN114917361A ADC-56 |
CN114917361A ADC-56 payload |
Undisclosed |
CN114917361A ADC-56 linker |
[145] | |
CN114917361A ADC-59 |
CN114917361A ADC-59 payload |
Undisclosed |
CN114917361A ADC-59 linker |
[145] | |
CN114917361A ADC-62 |
CN114917361A ADC-62 payload |
Undisclosed |
CN114917361A ADC-62 linker |
[145] | |
CN114917361A ADC-65 |
CN114917361A ADC-65 payload |
Undisclosed |
CN114917361A ADC-65 linker |
[145] | |
CN114917361A ADC-68 |
CN114917361A ADC-68 payload |
Undisclosed |
CN114917361A ADC-68 linker |
[145] | |
CN114917361A ADC-71 |
CN114917361A ADC-71 payload |
Undisclosed |
CN114917361A ADC-71 linker |
[145] | |
CN114917361A ADC-74 |
CN114917361A ADC-74 payload |
Undisclosed |
CN114917361A ADC-74 linker |
[145] | |
CN114917361A ADC-77 |
CN114917361A ADC-77 payload |
Undisclosed |
CN114917361A ADC-77 linker |
[145] | |
CN114917361A ADC-80 |
CN114917361A ADC-80 payload |
Undisclosed |
CN114917361A ADC-80 linker |
[145] | |
CN114917361A ADC-83 |
CN114917361A ADC-83 payload |
Undisclosed |
CN114917361A ADC-83 linker |
[145] | |
CN109641910A ADC-1 |
CN109641910A ADC-1 payload |
Undisclosed |
CN109641910A ADC-1 linker |
[146] | |
CN109641910A ADC-2 |
CN109641910A ADC-2 payload |
Undisclosed |
CN109641910A ADC-2 linker |
[146] | |
CN109641910A ADC-3 |
CN109641910A ADC-3 payload |
Undisclosed |
CN109641910A ADC-3 linker |
[146] | |
CN109641910A ADC-4 |
CN109641910A ADC-4 payload |
Undisclosed |
CN109641910A ADC-4 linker |
[146] | |
CN109641910A ADC-5 |
CN109641910A ADC-5 payload |
Undisclosed |
CN109641910A ADC-5 linker |
[146] | |
CN109641910A ADC-6 |
CN109641910A ADC-6 payload |
Undisclosed |
CN109641910A ADC-6 linker |
[146] | |
CN109641910A ADC-7 |
CN109641910A ADC-7 payload |
Undisclosed |
CN109641910A ADC-7 linker |
[146] | |
CN109641910A ADC-8 |
CN109641910A ADC-8 payload |
Undisclosed |
CN109641910A ADC-8 linker |
[146] | |
CN109641910A ADC-9 |
CN109641910A ADC-9 payload |
Undisclosed |
CN109641910A ADC-9 linker |
[146] | |
CN109641910A ADC-10 |
CN109641910A ADC-10 payload |
Undisclosed |
CN109641910A ADC-10 linker |
[146] | |
CN109641910A ADC-11 |
CN109641910A ADC-11 payload |
Undisclosed |
CN109641910A ADC-11 linker |
[146] | |
CN109641910A ADC-12 |
CN109641910A ADC-12 payload |
Undisclosed |
CN109641910A ADC-12 linker |
[146] | |
CN109641910A ADC-13 |
CN109641910A ADC-13 payload |
Undisclosed |
CN109641910A ADC-13 linker |
[146] | |
CN109641910A ADC-14 |
CN109641910A ADC-14 payload |
Undisclosed |
CN109641910A ADC-14 linker |
[146] | |
CN109641910A ADC-15 |
CN109641910A ADC-15 payload |
Undisclosed |
CN109641910A ADC-15 linker |
[146] | |
CN109641910A ADC-16 |
CN109641910A ADC-16 payload |
Undisclosed |
CN109641910A ADC-16 linker |
[146] | |
CN105051032B ADC-I-5 |
CN105051032B_ADC-I-5 payload |
Undisclosed |
CN105051032B_ADC-I-5 linker |
[147] | |
CN105051032B ADC-I-6 |
CN105051032B_ADC-I-6 payload |
Undisclosed |
CN105051032B_ADC-I-6 linker |
[147] | |
CN105051032B ADC-I-7 |
CN105051032B_ADC-I-7 payload |
Undisclosed |
CN105051032B_ADC-I-7 linker |
[147] | |
CN105051032B ADC-I-8 |
CN105051032B_ADC-I-8 payload |
Undisclosed |
CN105051032B_ADC-I-8 linker |
[147] | |
CN105051032B ADC-I-9 |
CN105051032B_ADC-I-9 payload |
Undisclosed |
CN105051032B_ADC-I-9 linker |
[147] | |
CN105051032B ADC-I-10 |
CN105051032B_ADC-I-10 payload |
Undisclosed |
CN105051032B_ADC-I-10 linker |
[147] | |
CN105051032B ADC-I-11 |
CN105051032B_ADC-I-11 payload |
Undisclosed |
CN105051032B_ADC-I-11 linker |
[147] | |
CN105051032B ADC-I-12 |
CN105051032B_ADC-I-12 payload |
Undisclosed |
CN105051032B_ADC-I-12 linker |
[147] | |
CN105051032B ADC-I-13 |
CN105051032B_ADC-I-13 payload |
Undisclosed |
CN105051032B_ADC-I-13 linker |
[147] | |
CN105051032B ADC-I-14 |
CN105051032B_ADC-I-14 payload |
Undisclosed |
CN105051032B_ADC-I-14 linker |
[147] | |
CN105051032B ADC-I-15 |
CN105051032B_ADC-I-15 payload |
Undisclosed |
CN105051032B_ADC-I-15 linker |
[147] | |
CN105051032B ADC-I-16 |
CN105051032B_ADC-I-16 payload |
Undisclosed |
CN105051032B_ADC-I-16 linker |
[147] | |
CN105051032B ADC-I-17 |
CN105051032B_ADC-I-17 payload |
Undisclosed |
CN105051032B_ADC-I-17 linker |
[147] | |
CN105051032B ADC-I-18 |
CN105051032B_ADC-I-18 payload |
Undisclosed |
CN105051032B_ADC-I-18 linker |
[147] | |
CN105051032B ADC-I-19 |
CN105051032B_ADC-I-19 payload |
Undisclosed |
CN105051032B_ADC-I-19 linker |
[147] | |
CN105051032B ADC-I-20 |
CN105051032B_ADC-I-20 payload |
Undisclosed |
CN105051032B_ADC-I-20 linker |
[147] | |
CN105051032B ADC-I-21 |
CN105051032B_ADC-I-21 payload |
Undisclosed |
CN105051032B_ADC-I-21 linker |
[147] | |
CN105051032B ADC-I-22 |
CN105051032B_ADC-I-22 payload |
Undisclosed |
CN105051032B_ADC-I-22 linker |
[147] | |
CN105051032B ADC-I-23 |
CN105051032B_ADC-I-23 payload |
Undisclosed |
CN105051032B_ADC-I-23 linker |
[147] | |
CN105051032B ADC-I-24 |
CN105051032B_ADC-I-24 payload |
Undisclosed |
CN105051032B_ADC-I-24 linker |
[147] | |
CN105051032B ADC-I-25 |
CN105051032B_ADC-I-25 payload |
Undisclosed |
CN105051032B_ADC-I-25 linker |
[147] | |
CN105051032B ADC-I-26 |
CN105051032B_ADC-I-26 payload |
Undisclosed |
CN105051032B_ADC-I-26 linker |
[147] | |
CN105051032B ADC-I-27 |
CN105051032B_ADC-I-27 payload |
Undisclosed |
CN105051032B_ADC-I-27 linker |
[147] | |
CN105051032B ADC-I-28 |
CN105051032B_ADC-I-28 payload |
Undisclosed |
CN105051032B_ADC-I-28 linker |
[147] | |
CN105051032B ADC-I-29 |
CN105051032B_ADC-I-29 payload |
Undisclosed |
CN105051032B_ADC-I-29 linker |
[147] | |
CN105051032B ADC-I-30 |
CN105051032B_ADC-I-30 payload |
Undisclosed |
CN105051032B_ADC-I-30 linker |
[147] | |
CN105051032B ADC-I-31 |
CN105051032B_ADC-I-31 payload |
Undisclosed |
CN105051032B_ADC-I-31 linker |
[147] | |
CN105051032B ADC-I-32 |
CN105051032B_ADC-I-32 payload |
Undisclosed |
CN105051032B_ADC-I-32 linker |
[147] | |
CN105051032B ADC-I-33 |
CN105051032B_ADC-I-33 payload |
Undisclosed |
CN105051032B_ADC-I-33 linker |
[147] | |
CN105051032B ADC-I-34 |
CN105051032B_ADC-I-34 payload |
Undisclosed |
CN105051032B_ADC-I-34 linker |
[147] | |
CN105051032B ADC-I-35 |
CN105051032B_ADC-I-35 payload |
Undisclosed |
CN105051032B_ADC-I-35 linker |
[147] | |
CN105051032B ADC-I-36 |
CN105051032B_ADC-I-36 payload |
Undisclosed |
CN105051032B_ADC-I-36 linker |
[147] | |
CN105051032B ADC-I-37 |
CN105051032B_ADC-I-37 payload |
Undisclosed |
CN105051032B_ADC-I-37 linker |
[147] | |
CN105051032B ADC-I-38 |
CN105051032B_ADC-I-38 payload |
Undisclosed |
CN105051032B_ADC-I-38 linker |
[147] | |
CN105051032B ADC-I-39 |
CN105051032B_ADC-I-39 payload |
Undisclosed |
CN105051032B_ADC-I-39 linker |
[147] | |
CN105051032B ADC-I-40 |
CN105051032B_ADC-I-40 payload |
Undisclosed |
CN105051032B_ADC-I-40 linker |
[147] | |
CN105051032B ADC-I-41 |
CN105051032B_ADC-I-41 payload |
Undisclosed |
CN105051032B_ADC-I-41 linker |
[147] | |
WO2014068443A1 ADC1 |
WO2014068443A1_ADC1 payload |
Undisclosed |
WO2014068443A1_ADC1 linker |
[148] | |
WO2014068443A1 ADC2 |
WO2014068443A1_ADC2 payload |
Undisclosed |
WO2014068443A1_ADC2 linker |
[148] | |
WO2014068443A1 ADC3 |
WO2014068443A1_ADC3 payload |
Undisclosed |
WO2014068443A1_ADC3 linker |
[148] | |
WO2014068443A1 ADC4 |
WO2014068443A1_ADC4 payload |
Undisclosed |
WO2014068443A1_ADC4 linker |
[148] | |
WO2014068443A1 ADC5 |
WO2014068443A1_ADC5 payload |
Undisclosed |
WO2014068443A1_ADC5 linker |
[148] | |
WO2014068443A1 ADC6 |
WO2014068443A1_ADC6 payload |
Undisclosed |
WO2014068443A1_ADC6 linker |
[148] | |
WO2014068443A1 ADC7 |
WO2014068443A1_ADC7 payload |
Undisclosed |
WO2014068443A1_ADC7 linker |
[148] | |
WO2014068443A1 ADC8 |
WO2014068443A1_ADC8 payload |
Undisclosed |
WO2014068443A1_ADC8 linker |
[148] | |
WO2014068443A1 ADC9 |
WO2014068443A1_ADC9 payload |
Undisclosed |
WO2014068443A1_ADC9 linker |
[148] | |
WO2014068443A1 ADC10 |
WO2014068443A1_ADC10 payload |
Undisclosed |
WO2014068443A1_ADC10 linker |
[148] | |
WO2014068443A1 ADC11 |
WO2014068443A1_ADC11 payload |
Undisclosed |
WO2014068443A1_ADC11 linker |
[148] | |
WO2014068443A1 ADC12 |
WO2014068443A1_ADC12 payload |
Undisclosed |
WO2014068443A1_ADC12 linker |
[148] | |
WO2014068443A1 ADC13 |
WO2014068443A1_ADC13 payload |
Undisclosed |
WO2014068443A1_ADC13 linker |
[148] | |
WO2014068443A1 ADC14 |
WO2014068443A1_ADC14 payload |
Undisclosed |
WO2014068443A1_ADC14 linker |
[148] | |
WO2014068443A1 ADC15 |
WO2014068443A1_ADC15 payload |
Undisclosed |
WO2014068443A1_ADC15 linker |
[148] | |
WO2014068443A1 ADC16 |
WO2014068443A1_ADC16 payload |
Undisclosed |
WO2014068443A1_ADC16 linker |
[148] | |
WO2014068443A1 ADC17 |
WO2014068443A1_ADC17 payload |
Undisclosed |
WO2014068443A1_ADC17 linker |
[148] | |
WO2014068443A1 ADC18 |
WO2014068443A1_ADC18 payload |
Undisclosed |
WO2014068443A1_ADC18 linker |
[148] | |
WO2014068443A1 ADC19 |
WO2014068443A1_ADC19 payload |
Undisclosed |
WO2014068443A1_ADC19 linker |
[148] | |
WO2014068443A1 ADC20 |
WO2014068443A1_ADC20 payload |
Undisclosed |
WO2014068443A1_ADC20 linker |
[148] | |
WO2014068443A1 ADC21 |
WO2014068443A1_ADC21 payload |
Undisclosed |
WO2014068443A1_ADC21 linker |
[148] | |
WO2014068443A1 ADC22 |
WO2014068443A1_ADC22 payload |
Undisclosed |
WO2014068443A1_ADC22 linker |
[148] | |
WO2014068443A1 ADC23 |
WO2014068443A1_ADC23 payload |
Undisclosed |
WO2014068443A1_ADC23 linker |
[148] | |
WO2014068443A1 ADC24 |
WO2014068443A1_ADC24 payload |
Undisclosed |
WO2014068443A1_ADC24 linker |
[148] | |
WO2014068443A1 ADC25 |
WO2014068443A1_ADC25 payload |
Undisclosed |
WO2014068443A1_ADC25 linker |
[148] | |
WO2014068443A1 ADC26 |
WO2014068443A1_ADC26 payload |
Undisclosed |
WO2014068443A1_ADC26 linker |
[148] | |
WO2014068443A1 ADC27 |
WO2014068443A1_ADC27 payload |
Undisclosed |
WO2014068443A1_ADC27 linker |
[148] | |
WO2014068443A1 ADC28 |
WO2014068443A1_ADC28 payload |
Undisclosed |
WO2014068443A1_ADC28 linker |
[148] | |
WO2014068443A1 ADC29 |
WO2014068443A1_ADC29 payload |
Undisclosed |
WO2014068443A1_ADC29 linker |
[148] | |
WO2014068443A1 ADC30 |
WO2014068443A1_ADC30 payload |
Undisclosed |
WO2014068443A1_ADC30 linker |
[148] | |
WO2014068443A1 ADC31 |
WO2014068443A1_ADC31 payload |
Undisclosed |
WO2014068443A1_ADC31 linker |
[148] | |
WO2014068443A1 ADC32 |
WO2014068443A1_ADC32 payload |
Undisclosed |
WO2014068443A1_ADC32 linker |
[148] | |
WO2014068443A1 ADC33 |
WO2014068443A1_ADC33 payload |
Undisclosed |
WO2014068443A1_ADC33 linker |
[148] | |
WO2014068443A1 ADC34 |
WO2014068443A1_ADC34 payload |
Undisclosed |
WO2014068443A1_ADC34 linker |
[148] | |
WO2014068443A1 ADC35 |
WO2014068443A1_ADC35 payload |
Undisclosed |
WO2014068443A1_ADC35 linker |
[148] | |
WO2014068443A1 ADC36 |
WO2014068443A1_ADC36 payload |
Undisclosed |
WO2014068443A1_ADC36 linker |
[148] | |
WO2014068443A1 ADC37 |
WO2014068443A1_ADC37 payload |
Undisclosed |
WO2014068443A1_ADC37 linker |
[148] | |
WO2014068443A1 ADC38 |
WO2014068443A1_ADC38 payload |
Undisclosed |
WO2014068443A1_ADC38 linker |
[148] | |
WO2014068443A1 ADC39 |
WO2014068443A1_ADC39 payload |
Undisclosed |
WO2014068443A1_ADC39 linker |
[148] | |
WO2014068443A1 ADC40 |
WO2014068443A1_ADC40 payload |
Undisclosed |
WO2014068443A1_ADC40 linker |
[148] | |
WO2014068443A1 ADC41 |
WO2014068443A1_ADC41 payload |
Undisclosed |
WO2014068443A1_ADC41 linker |
[148] | |
WO2014068443A1 ADC42 |
WO2014068443A1_ADC42 payload |
Undisclosed |
WO2014068443A1_ADC42 linker |
[148] | |
WO2014068443A1 ADC43 |
WO2014068443A1_ADC43 payload |
Undisclosed |
WO2014068443A1_ADC43 linker |
[148] | |
WO2014068443A1 ADC44 |
WO2014068443A1_ADC44 payload |
Undisclosed |
WO2014068443A1_ADC44 linker |
[148] | |
WO2014068443A1 ADC45 |
WO2014068443A1_ADC45 payload |
Undisclosed |
WO2014068443A1_ADC45 linker |
[148] | |
WO2014068443A1 ADC46 |
WO2014068443A1_ADC46 payload |
Undisclosed |
WO2014068443A1_ADC46 linker |
[148] | |
WO2014068443A1 ADC47 |
WO2014068443A1_ADC47 payload |
Undisclosed |
WO2014068443A1_ADC47 linker |
[148] | |
WO2014068443A1 ADC48 |
WO2014068443A1_ADC48 payload |
Undisclosed |
WO2014068443A1_ADC48 linker |
[148] | |
WO2014068443A1 ADC49 |
WO2014068443A1_ADC49 payload |
Undisclosed |
WO2014068443A1_ADC49 linker |
[148] | |
WO2014068443A1 ADC50 |
WO2014068443A1_ADC50 payload |
Undisclosed |
WO2014068443A1_ADC50 linker |
[148] | |
WO2014068443A1 ADC51 |
WO2014068443A1_ADC51 payload |
Undisclosed |
WO2014068443A1_ADC51 linker |
[148] | |
WO2014068443A1 ADC52 |
WO2014068443A1_ADC52 payload |
Undisclosed |
WO2014068443A1_ADC52 linker |
[148] | |
WO2014068443A1 ADC53 |
WO2014068443A1_ADC53 payload |
Undisclosed |
WO2014068443A1_ADC53 linker |
[148] | |
WO2014068443A1 ADC54 |
WO2014068443A1_ADC54 payload |
Undisclosed |
WO2014068443A1_ADC54 linker |
[148] | |
WO2014068443A1 ADC55 |
WO2014068443A1_ADC55 payload |
Undisclosed |
WO2014068443A1_ADC55 linker |
[148] | |
WO2014068443A1 ADC56 |
WO2014068443A1_ADC56 payload |
Undisclosed |
WO2014068443A1_ADC56 linker |
[148] | |
WO2014068443A1 ADC57 |
WO2014068443A1_ADC57 payload |
Undisclosed |
WO2014068443A1_ADC57 linker |
[148] | |
WO2014068443A1 ADC58 |
WO2014068443A1_ADC58 payload |
Undisclosed |
WO2014068443A1_ADC58 linker |
[148] | |
WO2014068443A1 ADC59 |
WO2014068443A1_ADC59 payload |
Undisclosed |
WO2014068443A1_ADC59 linker |
[148] | |
WO2014068443A1 ADC60 |
WO2014068443A1_ADC60 payload |
Undisclosed |
WO2014068443A1_ADC60 linker |
[148] | |
WO2014068443A1 ADC61 |
WO2014068443A1_ADC61 payload |
Undisclosed |
WO2014068443A1_ADC61 linker |
[148] | |
WO2014068443A1 ADC62 |
WO2014068443A1_ADC62 payload |
Undisclosed |
WO2014068443A1_ADC62 linker |
[148] | |
WO2014068443A1 ADC63 |
WO2014068443A1_ADC63 payload |
Undisclosed |
WO2014068443A1_ADC63 linker |
[148] | |
WO2014068443A1 ADC64 |
WO2014068443A1_ADC64 payload |
Undisclosed |
WO2014068443A1_ADC64 linker |
[148] | |
WO2014068443A1 ADC65 |
WO2014068443A1_ADC65 payload |
Undisclosed |
WO2014068443A1_ADC65 linker |
[148] | |
WO2014068443A1 ADC66 |
WO2014068443A1_ADC66 payload |
Undisclosed |
WO2014068443A1_ADC66 linker |
[148] | |
WO2014068443A1 ADC67 |
WO2014068443A1_ADC67 payload |
Undisclosed |
WO2014068443A1_ADC67 linker |
[148] | |
WO2014068443A1 ADC68 |
WO2014068443A1_ADC68 payload |
Undisclosed |
WO2014068443A1_ADC68 linker |
[148] | |
WO2014068443A1 ADC69 |
WO2014068443A1_ADC69 payload |
Undisclosed |
WO2014068443A1_ADC69 linker |
[148] | |
WO2014068443A1 ADC70 |
WO2014068443A1_ADC70 payload |
Undisclosed |
WO2014068443A1_ADC70 linker |
[148] | |
WO2014068443A1 ADC71 |
WO2014068443A1_ADC71 payload |
Undisclosed |
WO2014068443A1_ADC71 linker |
[148] | |
WO2014068443A1 ADC72 |
WO2014068443A1_ADC72 payload |
Undisclosed |
WO2014068443A1_ADC72 linker |
[148] | |
WO2014068443A1 ADC73 |
WO2014068443A1_ADC73 payload |
Undisclosed |
WO2014068443A1_ADC73 linker |
[148] | |
WO2014068443A1 ADC74 |
WO2014068443A1_ADC74 payload |
Undisclosed |
WO2014068443A1_ADC74 linker |
[148] | |
WO2014068443A1 ADC75 |
WO2014068443A1_ADC75 payload |
Undisclosed |
WO2014068443A1_ADC75 linker |
[148] | |
WO2014068443A1 ADC76 |
WO2014068443A1_ADC76 payload |
Undisclosed |
WO2014068443A1_ADC76 linker |
[148] | |
WO2014068443A1 ADC77 |
WO2014068443A1_ADC77 payload |
Undisclosed |
WO2014068443A1_ADC77 linker |
[148] | |
WO2014068443A1 ADC78 |
WO2014068443A1_ADC78 payload |
Undisclosed |
WO2014068443A1_ADC78 linker |
[148] | |
WO2014068443A1 ADC79 |
WO2014068443A1_ADC79 payload |
Undisclosed |
WO2014068443A1_ADC79 linker |
[148] | |
WO2014068443A1 ADC80 |
WO2014068443A1_ADC80 payload |
Undisclosed |
WO2014068443A1_ADC80 linker |
[148] | |
WO2014068443A1 ADC81 |
WO2014068443A1_ADC81 payload |
Undisclosed |
WO2014068443A1_ADC81 linker |
[148] | |
WO2014068443A1 ADC82 |
WO2014068443A1_ADC82 payload |
Undisclosed |
WO2014068443A1_ADC82 linker |
[148] | |
WO2014068443A1 ADC83 |
WO2014068443A1_ADC83 payload |
Undisclosed |
WO2014068443A1_ADC83 linker |
[148] | |
WO2014068443A1 ADC84 |
WO2014068443A1_ADC84 payload |
Undisclosed |
WO2014068443A1_ADC84 linker |
[148] | |
TAA-013 |
Mertansine DM1 |
Microtubule (MT) |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) |
[149] | |
ADCT-502 |
SG3199 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[150] | |
Trastuzumab-dTSPEG-MMAF |
Monomethyl auristatin F |
Microtubule (MT) |
dTSPEG |
[151] |
Trastuzumab A114C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Neolymphostin ADC 21 |
Neolymphostin A |
3-Phosphoinositide-dependent protein kinase 1 (PDPK1) |
Mc-Val-Cit-PABC-DMEA |
[152] | |
Neolymphostin ADC 22 |
Neolymphostin A |
3-Phosphoinositide-dependent protein kinase 1 (PDPK1) |
PEG4-DMEA |
[152] | |
Neolymphostin ADC 23 |
Neolymphostin A |
3-Phosphoinositide-dependent protein kinase 1 (PDPK1) |
Mc-Val-Cit-PABC |
[152] | |
Neolymphostin ADC 24 |
Neolymphostin A |
3-Phosphoinositide-dependent protein kinase 1 (PDPK1) |
N-Methoxycarbonylmaleimide |
[152] |
Trastuzumab D265C
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
T-D265C-CN-Pro-amanitin |
CN-Pro-dideoxy-alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mal-Val-Ala-PAB |
[153] | |
T-D265C-NH2-Pro-amanitin |
NH2-Pro-dideoxy-alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[153] | |
T-D265C-OH-Pro-amanitin |
OH-Pro-dideoxy-alpha-amanitin |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G) |
Mc-Val-Ala-PABC |
[153] |
Trastuzumab I253Q
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Trastuzumab I253Q-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Dansylcadaverine-BCN based linker |
[154] | |
Trastuzumab deglycosylated WT-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Dansylcadaverine deglycosylated-BCN based linker |
[154] |
Trastuzumab N297A
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ADC MMAE/F 4+2 |
Monomethyl auristatin E+Monomethyl auristatin F |
Microtubule (MT) |
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC |
[155] | |
ADC MMAE/F 2+4 |
Monomethyl auristatin E+Monomethyl auristatin F |
Microtubule (MT) |
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC |
[155] | |
ADC MMAE/F 2+2 |
Monomethyl auristatin E+Monomethyl auristatin F |
Microtubule (MT) |
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC |
[155] |
Trastuzumab scFv
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
scFv(Herceptin)-PE-STXA |
PE15-Stx 2a |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[156] | |
scFv (Herceptin)-PE |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[156] | |
scFv(trastuzumab)-PE38KDEL |
Pseudomonas exotoxin PE38 |
Eukaryotic elongation factor 2 (EEF2) |
Undisclosed |
[11] |
Trastuzumab-AL1
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
IgG1 (trastuzumab)-AL1-MMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Undisclosed |
[11] |
Trastuzumab-CpHK
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
T-CpHK-Tet-ADC |
Monomethyl auristatin E |
Microtubule (MT) |
Tetrazine-PEG5-Val-Ala-PABC |
[157] | |
T-CpHK-Mal-ADC |
Monomethyl auristatin E |
Microtubule (MT) |
Mc-Val-Cit-PABC |
[157] |
Trastuzumab-Flexmab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Trastuzumab-Flexmab-SG3710 |
SG3199 |
Human Deoxyribonucleic acid (hDNA) |
Mal-PEG8-Val-Ala-PABC |
[84] |
WO2015095301A2 ADC-1 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-1 |
WO2015095301A2 ADC-1 payload |
Undisclosed |
WO2015095301A2 ADC-1 linker |
[6] |
WO2015095301A2 ADC-10 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-10 |
WO2015095301A2 ADC-10 payload |
Undisclosed |
WO2015095301A2 ADC-10 linker |
[6] |
WO2015095301A2 ADC-11 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-11 |
WO2015095301A2 ADC-11 payload |
Undisclosed |
WO2015095301A2 ADC-11 linker |
[6] |
WO2015095301A2 ADC-12 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-12 |
WO2015095301A2 ADC-12 payload |
Undisclosed |
WO2015095301A2 ADC-12 linker |
[6] |
WO2015095301A2 ADC-13 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-13 |
WO2015095301A2 ADC-13 payload |
Undisclosed |
WO2015095301A2 ADC-13 linker |
[6] |
WO2015095301A2 ADC-14 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-14 |
WO2015095301A2 ADC-14 payload |
Undisclosed |
WO2015095301A2 ADC-14 linker |
[6] |
WO2015095301A2 ADC-15 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-15 |
WO2015095301A2 ADC-15 payload |
Undisclosed |
WO2015095301A2 ADC-15 linker |
[6] |
WO2015095301A2 ADC-16 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-16 |
WO2015095301A2 ADC-16 payload |
Undisclosed |
WO2015095301A2 ADC-16 linker |
[6] |
WO2015095301A2 ADC-17 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-17 |
WO2015095301A2 ADC-17 payload |
Undisclosed |
WO2015095301A2 ADC-17 linker |
[6] |
WO2015095301A2 ADC-18 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-18 |
WO2015095301A2 ADC-18 payload |
Undisclosed |
WO2015095301A2 ADC-18 linker |
[6] |
WO2015095301A2 ADC-19 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-19 |
WO2015095301A2 ADC-19 payload |
Undisclosed |
WO2015095301A2 ADC-19 linker |
[6] |
WO2015095301A2 ADC-2 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-2 |
WO2015095301A2 ADC-2 payload |
Undisclosed |
WO2015095301A2 ADC-2 linker |
[6] |
WO2015095301A2 ADC-20 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-20 |
WO2015095301A2 ADC-20 payload |
Undisclosed |
WO2015095301A2 ADC-20 linker |
[6] |
WO2015095301A2 ADC-21 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-21 |
WO2015095301A2 ADC-21 payload |
Undisclosed |
WO2015095301A2 ADC-21 linker |
[6] |
WO2015095301A2 ADC-22 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-22 |
WO2015095301A2 ADC-22 payload |
Undisclosed |
WO2015095301A2 ADC-22 linker |
[6] |
WO2015095301A2 ADC-23 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-23 |
WO2015095301A2 ADC-23 payload |
Undisclosed |
WO2015095301A2 ADC-23 linker |
[6] |
WO2015095301A2 ADC-24 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-24 |
WO2015095301A2 ADC-24 payload |
Undisclosed |
WO2015095301A2 ADC-24 linker |
[6] |
WO2015095301A2 ADC-25 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-25 |
WO2015095301A2 ADC-25 payload |
Undisclosed |
WO2015095301A2 ADC-25 linker |
[6] |
WO2015095301A2 ADC-26 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-26 |
WO2015095301A2 ADC-26 payload |
Undisclosed |
WO2015095301A2 ADC-26 linker |
[6] |
WO2015095301A2 ADC-27 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-27 |
WO2015095301A2 ADC-27 payload |
Undisclosed |
WO2015095301A2 ADC-27 linker |
[6] |
WO2015095301A2 ADC-3 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-3 |
WO2015095301A2 ADC-3 payload |
Undisclosed |
WO2015095301A2 ADC-3 linker |
[6] |
WO2015095301A2 ADC-4 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-4 |
WO2015095301A2 ADC-4 payload |
Undisclosed |
WO2015095301A2 ADC-4 linker |
[6] |
WO2015095301A2 ADC-5 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-5 |
WO2015095301A2 ADC-5 payload |
Undisclosed |
WO2015095301A2 ADC-5 linker |
[6] |
WO2015095301A2 ADC-6 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-6 |
WO2015095301A2 ADC-6 payload |
Undisclosed |
WO2015095301A2 ADC-6 linker |
[6] |
WO2015095301A2 ADC-7 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-7 |
WO2015095301A2 ADC-7 payload |
Undisclosed |
WO2015095301A2 ADC-7 linker |
[6] |
WO2015095301A2 ADC-8 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-8 |
WO2015095301A2 ADC-8 payload |
Undisclosed |
WO2015095301A2 ADC-8 linker |
[6] |
WO2015095301A2 ADC-9 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015095301A2 ADC-9 |
WO2015095301A2 ADC-9 payload |
Undisclosed |
WO2015095301A2 ADC-9 linker |
[6] |
WO2015189791A1 ADC-1 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-1 |
WO2015189791A1 ADC-1 payload |
Undisclosed |
WO2015189791A1 ADC-1 linker |
[7] |
WO2015189791A1 ADC-10 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-10 |
WO2015189791A1 ADC-10 payload |
Undisclosed |
WO2015189791A1 ADC-10 linker |
[7] |
WO2015189791A1 ADC-11 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-11 |
WO2015189791A1 ADC-11 payload |
Undisclosed |
WO2015189791A1 ADC-11 linker |
[7] |
WO2015189791A1 ADC-12 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-12 |
WO2015189791A1 ADC-12 payload |
Undisclosed |
WO2015189791A1 ADC-12 linker |
[7] |
WO2015189791A1 ADC-13 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-13 |
WO2015189791A1 ADC-13 payload |
Undisclosed |
WO2015189791A1 ADC-13 linker |
[7] |
WO2015189791A1 ADC-14 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-14 |
WO2015189791A1 ADC-14 payload |
Undisclosed |
WO2015189791A1 ADC-14 linker |
[7] |
WO2015189791A1 ADC-15 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-15 |
WO2015189791A1 ADC-15 payload |
Undisclosed |
WO2015189791A1 ADC-15 linker |
[7] |
WO2015189791A1 ADC-16 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-16 |
WO2015189791A1 ADC-16 payload |
Undisclosed |
WO2015189791A1 ADC-16 linker |
[7] |
WO2015189791A1 ADC-17 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-17 |
WO2015189791A1 ADC-17 payload |
Undisclosed |
WO2015189791A1 ADC-17 linker |
[7] |
WO2015189791A1 ADC-18 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-18 |
WO2015189791A1 ADC-18 payload |
Undisclosed |
WO2015189791A1 ADC-18 linker |
[7] |
WO2015189791A1 ADC-19 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-19 |
WO2015189791A1 ADC-19 payload |
Undisclosed |
WO2015189791A1 ADC-19 linker |
[7] |
WO2015189791A1 ADC-2 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-2 |
WO2015189791A1 ADC-2 payload |
Undisclosed |
WO2015189791A1 ADC-2 linker |
[7] |
WO2015189791A1 ADC-20 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-20 |
WO2015189791A1 ADC-20 payload |
Undisclosed |
WO2015189791A1 ADC-20 linker |
[7] |
WO2015189791A1 ADC-21 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-21 |
WO2015189791A1 ADC-21 payload |
Undisclosed |
WO2015189791A1 ADC-21 linker |
[7] |
WO2015189791A1 ADC-22 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-22 |
WO2015189791A1 ADC-22 payload |
Undisclosed |
WO2015189791A1 ADC-22 linker |
[7] |
WO2015189791A1 ADC-23 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-23 |
WO2015189791A1 ADC-23 payload |
Undisclosed |
WO2015189791A1 ADC-23 linker |
[7] |
WO2015189791A1 ADC-24 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-24 |
WO2015189791A1 ADC-24 payload |
Undisclosed |
WO2015189791A1 ADC-24 linker |
[7] |
WO2015189791A1 ADC-25 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-25 |
WO2015189791A1 ADC-25 payload |
Undisclosed |
WO2015189791A1 ADC-25 linker |
[7] |
WO2015189791A1 ADC-26 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-26 |
WO2015189791A1 ADC-26 payload |
Undisclosed |
WO2015189791A1 ADC-26 linker |
[7] |
WO2015189791A1 ADC-3 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-3 |
WO2015189791A1 ADC-3 payload |
Undisclosed |
WO2015189791A1 ADC-3 linker |
[7] |
WO2015189791A1 ADC-38 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-38 |
WO2015189791A1 ADC-38 payload |
Undisclosed |
WO2015189791A1 ADC-38 linker |
[7] |
WO2015189791A1 ADC-39 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-39 |
WO2015189791A1 ADC-39 payload |
Undisclosed |
WO2015189791A1 ADC-39 linker |
[7] |
WO2015189791A1 ADC-4 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-4 |
WO2015189791A1 ADC-4 payload |
Undisclosed |
WO2015189791A1 ADC-4 linker |
[7] |
WO2015189791A1 ADC-41 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-41 |
WO2015189791A1 ADC-41 payload |
Undisclosed |
WO2015189791A1 ADC-41 linker |
[7] |
WO2015189791A1 ADC-42 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-42 |
WO2015189791A1 ADC-42 payload |
Undisclosed |
WO2015189791A1 ADC-42 linker |
[7] |
WO2015189791A1 ADC-43 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-43 |
WO2015189791A1 ADC-43 payload |
Undisclosed |
WO2015189791A1 ADC-43 linker |
[7] |
WO2015189791A1 ADC-44 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-44 |
WO2015189791A1 ADC-44 payload |
Undisclosed |
WO2015189791A1 ADC-44 linker |
[7] |
WO2015189791A1 ADC-45 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-45 |
WO2015189791A1 ADC-45 payload |
Undisclosed |
WO2015189791A1 ADC-45 linker |
[7] |
WO2015189791A1 ADC-46 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-46 |
WO2015189791A1 ADC-46 payload |
Undisclosed |
WO2015189791A1 ADC-46 linker |
[7] |
WO2015189791A1 ADC-47 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-47 |
WO2015189791A1 ADC-47 payload |
Undisclosed |
WO2015189791A1 ADC-47 linker |
[7] |
WO2015189791A1 ADC-48 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-48 |
WO2015189791A1 ADC-48 payload |
Undisclosed |
WO2015189791A1 ADC-48 linker |
[7] |
WO2015189791A1 ADC-49 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-49 |
WO2015189791A1 ADC-49 payload |
Undisclosed |
WO2015189791A1 ADC-49 linker |
[7] |
WO2015189791A1 ADC-5 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-5 |
WO2015189791A1 ADC-5 payload |
Undisclosed |
WO2015189791A1 ADC-5 linker |
[7] |
WO2015189791A1 ADC-50 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-50 |
WO2015189791A1 ADC-50 payload |
Undisclosed |
WO2015189791A1 ADC-50 linker |
[7] |
WO2015189791A1 ADC-51 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-51 |
WO2015189791A1 ADC-51 payload |
Undisclosed |
WO2015189791A1 ADC-51 linker |
[7] |
WO2015189791A1 ADC-52 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-52 |
WO2015189791A1 ADC-52 payload |
Undisclosed |
WO2015189791A1 ADC-52 linker |
[7] |
WO2015189791A1 ADC-53 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-53 |
WO2015189791A1 ADC-53 payload |
Undisclosed |
WO2015189791A1 ADC-53 linker |
[7] |
WO2015189791A1 ADC-54 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-54 |
WO2015189791A1 ADC-54 payload |
Undisclosed |
WO2015189791A1 ADC-54 linker |
[7] |
WO2015189791A1 ADC-55 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-55 |
WO2015189791A1 ADC-55 payload |
Undisclosed |
WO2015189791A1 ADC-55 linker |
[7] |
WO2015189791A1 ADC-56 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-56 |
WO2015189791A1 ADC-56 payload |
Undisclosed |
WO2015189791A1 ADC-56 linker |
[7] |
WO2015189791A1 ADC-57 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-57 |
WO2015189791A1 ADC-57 payload |
Undisclosed |
WO2015189791A1 ADC-57 linker |
[7] |
WO2015189791A1 ADC-58 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-58 |
WO2015189791A1 ADC-58 payload |
Undisclosed |
WO2015189791A1 ADC-58 linker |
[7] |
WO2015189791A1 ADC-59 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-59 |
WO2015189791A1 ADC-59 payload |
Undisclosed |
WO2015189791A1 ADC-59 linker |
[7] |
WO2015189791A1 ADC-6 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-6 |
WO2015189791A1 ADC-6 payload |
Undisclosed |
WO2015189791A1 ADC-6 linker |
[7] |
WO2015189791A1 ADC-60 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-60 |
WO2015189791A1 ADC-60 payload |
Undisclosed |
WO2015189791A1 ADC-60 linker |
[7] |
WO2015189791A1 ADC-62 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-62 |
WO2015189791A1 ADC-62 payload |
Undisclosed |
WO2015189791A1 ADC-62 linker |
[7] |
WO2015189791A1 ADC-65 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-65 |
WO2015189791A1 ADC-65 payload |
Undisclosed |
WO2015189791A1 ADC-65 linker |
[7] |
WO2015189791A1 ADC-7 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-7 |
WO2015189791A1 ADC-7 payload |
Undisclosed |
WO2015189791A1 ADC-7 linker |
[7] |
WO2015189791A1 ADC-8 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-8 |
WO2015189791A1 ADC-8 payload |
Undisclosed |
WO2015189791A1 ADC-8 linker |
[7] |
WO2015189791A1 ADC-9 antibody
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
WO2015189791A1 ADC-9 |
WO2015189791A1 ADC-9 payload |
Undisclosed |
WO2015189791A1 ADC-9 linker |
[7] |
XMT-1519
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
XMT-1522 |
Auristatin F hydroxypropylamide (AF-HPA) |
Microtubule (MT) |
Fleximer polymer |
[158] |
Zanidatamab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
Zanidatamab-ADC-Tb3-1 |
Zanidatamab-ADC-Tb3-1 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-1 linker |
[2] | |
Zanidatamab-ADC-Tb3-2 |
Zanidatamab-ADC-Tb3-2 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-2 linker |
[2] | |
Zanidatamab-ADC-Tb3-3 |
Zanidatamab-ADC-Tb3-3 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-3 linker |
[2] | |
Zanidatamab-ADC-Tb3-4 |
Zanidatamab-ADC-Tb3-4 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-4 linker |
[2] | |
Zanidatamab-ADC-Tb3-5 |
Zanidatamab-ADC-Tb3-5 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-5 linker |
[2] | |
Zanidatamab-ADC-Tb3-6 |
Zanidatamab-ADC-Tb3-6 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-6 linker |
[2] | |
Zanidatamab-ADC-Tb3-7 |
Zanidatamab-ADC-Tb3-7 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-7 linker |
[2] | |
Zanidatamab-ADC-Tb3-8 |
Zanidatamab-ADC-Tb3-8 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-8 linker |
[2] | |
Zanidatamab-ADC-Tb3-9 |
Zanidatamab-ADC-Tb3-9 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-9 linker |
[2] | |
Zanidatamab-ADC-Tb3-10 |
Zanidatamab-ADC-Tb3-10 payload |
Undisclosed |
Zanidatamab-ADC-Tb3-10 linker |
[2] |
ZHER2-ABD
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ZHER2-ABD-mcMMAF |
Monomethyl auristatin F |
Microtubule (MT) |
Maleimido-caproyl |
[159] | |
ZHER2-ABD-mcMMAE |
Monomethyl auristatin E |
Microtubule (MT) |
Maleimido-caproyl |
[159] |
ZHER2:342-Cupid-His
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
ZHER2:342-Cupid-His-Ax-SiPc |
Silicon Phthalocyanine |
Undisclosed |
Psyche-Ax |
[160] |
Zr-labeled trastuzumab
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
89Zr-DFO-T-DM1 |
Mertansine DM1 |
Microtubule (MT) |
Undisclosed |
[121] |
Undisclosed
ADC Info | ADC Name | Payload | Target | Linker | Ref |
---|---|---|---|---|---|
DB-1303 |
P1003 |
DNA topoisomerase 1 (TOP1) |
Mc-Gly-Gly-Phe-Gly |
[161] | |
IBI-354 |
DX-8951 derivative (DXd) |
DNA topoisomerase 1 (TOP1) |
PODS-CHX-A"-DTPA |
[162] | |
FDA-022 |
Topoisomerase I inhibitor |
DNA topoisomerase 1 (TOP1) |
Undisclosed |
[163] | |
ALT-P7 |
Undisclosed |
Undisclosed |
Undisclosed |
[164] | |
BAT-8010 |
Undisclosed |
Undisclosed |
Undisclosed |
[165] | |
BL-M07D1 |
Undisclosed |
Undisclosed |
Undisclosed |
[166] | |
GB-251 |
Undisclosed |
Undisclosed |
Undisclosed |
[34] | |
GQ-1005 |
Undisclosed |
Undisclosed |
Undisclosed |
[167] | |
GQ-1007 |
Undisclosed |
Undisclosed |
Undisclosed |
[167] | |
BI-CON-02 |
Undisclosed |
Undisclosed |
Undisclosed |
[168] | |
XMT-2056 |
Undisclosed |
Undisclosed |
Undisclosed |
[169] | |
ZV-0203 |
Undisclosed |
Undisclosed |
Undisclosed |
[41] | |
ZV203 |
Undisclosed |
Undisclosed |
Undisclosed |
[170] | |
FDA022-BB05 |
Undisclosed |
Undisclosed |
Undisclosed |
[171] | |
Recombinant anti-HER2 humanized mAb-DM1 |
Undisclosed |
Undisclosed |
Undisclosed |
[172] | |
HS630 |
Mertansine DM1 |
Microtubule (MT) |
Undisclosed |
[173] | |
MT-5111 |
Shiga toxin B subunit (StxB) |
Ribosome (RB) |
Undisclosed |
[173] | |
KM254-ADC |
Undisclosed |
Undisclosed |
Undisclosed |
[174] | |
Xl-250 |
Undisclosed |
Undisclosed |
Undisclosed |
[175] | |
Anti-HER2 antibody-drug conjugate (XDCExplorer) |
Undisclosed |
Undisclosed |
Undisclosed |
[176] | |
YB1-ADC-HER2 |
Undisclosed |
Undisclosed |
Undisclosed |
[177] | |
Biparatopic HER2/HER2 antibody drug conjugate |
Undisclosed |
Undisclosed |
Undisclosed |
[178] | |
Anti-HER2-4AP ADC |
Undisclosed |
Undisclosed |
Undisclosed |
[179] | |
Anti-HER2 antibody drug conjugate (NBE-Therapeutics) |
Undisclosed |
Undisclosed |
Undisclosed |
[180] | |
Anti-HER2 antibody-drug conjugate (Mersana Therapeutics/Genentech) |
Undisclosed |
Undisclosed |
Undisclosed |
[181] | |
Second Generation HER2-Directed Antibody-Drug conjugate |
Undisclosed |
Undisclosed |
Undisclosed |
[182] | |
Chloromethylbenz-Indoline Dimer Antibody Drug conjugate |
Undisclosed |
Undisclosed |
Undisclosed |
[183] | |
XB3-001 |
Undisclosed |
Undisclosed |
Undisclosed |
[184] | |
ANT-043 |
Undisclosed |
Undisclosed |
Undisclosed |
[185] | |
AbGn-110 |
Undisclosed |
Undisclosed |
Undisclosed |
[186] | |
CTAT-ADC |
Mertansine DM1 |
Microtubule (MT) |
Undisclosed |
[187] | |
Humanized Anti-HER2 Mab-Maytansine Conjugate |
Mertansine DM1 |
Microtubule (MT) |
Undisclosed |
[188] | |
DAN-311 |
Camptothecin |
DNA topoisomerase 1 (TOP1) |
Undisclosed |
[189] | |
SMP-656 |
Eribulin |
Microtubule (MT) |
Unique hydrophilic Linker |
[190] | |
JAB-BX400 |
STING agonist |
Stimulator of interferon genes protein (STING1) |
Undisclosed |
[191] | |
QBK249-G |
Undisclosed |
Undisclosed |
Undisclosed |
[192] | |
Mabion-HER2 ADC |
Undisclosed |
Undisclosed |
Undisclosed |
[193] | |
Antibody drug conjugate targeting HER2 (IntoCell) |
Undisclosed |
Undisclosed |
Undisclosed |
[194] | |
TE-1218 |
Undisclosed |
Undisclosed |
Undisclosed |
[195] | |
TE-1112 |
Undisclosed |
Undisclosed |
Undisclosed |
[196] | |
Antibody-drug conjugate (Scripps) |
Undisclosed |
Undisclosed |
Undisclosed |
[197] |
Tissue/Disease specific Abundances of This Antigen
Tissue specific Abundances of This Antigen
ICD Disease Classification 01
Bacterial infection [ICD-11: 1A00-1C4Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Gingival | |
The Specific Disease | Bacterial infection of gingival | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.012604643; Fold-change: -0.227313462; Z-score: -0.343912121 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 02
Brain cancer [ICD-11: 2A00]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Brainstem | |
The Specific Disease | Glioma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.198499823; Fold-change: 0.206253875; Z-score: 1.788174987 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | White matter | |
The Specific Disease | Glioma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.205668842; Fold-change: -0.145158484; Z-score: -0.935526231 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Brainstem | |
The Specific Disease | Neuroectodermal tumor | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.010609917; Fold-change: 0.220914299; Z-score: 0.586649079 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Nervous | |
The Specific Disease | Brain cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.000474019; Fold-change: -0.143646903; Z-score: -0.35944008 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Chronic myeloid leukemia [ICD-11: 2A20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Polycythemia vera | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.239499347; Fold-change: -0.01603947; Z-score: -0.077605035 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Whole blood | |
The Specific Disease | Myelofibrosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.328573514; Fold-change: 0.125386027; Z-score: 0.624530572 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
MyeloDysplastic syndromes [ICD-11: 2A37]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bone marrow | |
The Specific Disease | Myelodysplastic syndromes | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.876154929; Fold-change: -0.001779038; Z-score: -0.011801104 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.016265287; Fold-change: -0.192996315; Z-score: -2.408343389 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Lymphoma [ICD-11: 2A90- 2A85]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Tonsil | |
The Specific Disease | Lymphoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.336092708; Fold-change: -0.161654757; Z-score: -0.815441813 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Gastric cancer [ICD-11: 2B72]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Gastric | |
The Specific Disease | Gastric cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.002782765; Fold-change: 0.585165915; Z-score: 4.114824985 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 1.49E-08; Fold-change: 0.204756047; Z-score: 0.891446921 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Colon cancer [ICD-11: 2B90]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Colon | |
The Specific Disease | Colon cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 2.99E-17; Fold-change: -0.616192168; Z-score: -0.880827727 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.780532435; Fold-change: 0.108718842; Z-score: 0.155182797 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Pancreatic cancer [ICD-11: 2C10]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Pancreas | |
The Specific Disease | Pancreatic cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.302298466; Fold-change: 0.069838359; Z-score: 0.150669986 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.782977459; Fold-change: -0.164975563; Z-score: -0.417006613 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Liver cancer [ICD-11: 2C12]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Liver | |
The Specific Disease | Liver cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.151225689; Fold-change: -0.073324858; Z-score: -0.157294246 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.589664963; Fold-change: -0.014761025; Z-score: -0.042519418 | |
The Expression Level of Disease Section Compare with the Other Disease Section | p-value: 0.790092503; Fold-change: -0.187685505; Z-score: -0.549772705 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Lung cancer [ICD-11: 2C25]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Lung | |
The Specific Disease | Lung cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.000713882; Fold-change: -0.126046922; Z-score: -0.191222969 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.00351809; Fold-change: -0.110186279; Z-score: -0.139814236 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Melanoma [ICD-11: 2C30]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Melanoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.084824536; Fold-change: -0.263316526; Z-score: -0.576627257 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Sarcoma [ICD-11: 2C35]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Muscle | |
The Specific Disease | Sarcoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 4.42E-31; Fold-change: -0.276885656; Z-score: -0.852405448 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.259415131; Fold-change: -0.443169741; Z-score: -1.219076625 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Breast cancer [ICD-11: 2C60]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Breast | |
The Specific Disease | Breast cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 3.50E-77; Fold-change: 0.490641074; Z-score: 1.120664442 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 6.69E-13; Fold-change: 0.354032542; Z-score: 0.624640369 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Ovarian cancer [ICD-11: 2C73]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Ovarian | |
The Specific Disease | Ovarian cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.000490484; Fold-change: 0.452221886; Z-score: 1.023085171 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.230081828; Fold-change: 0.231462076; Z-score: 0.282151742 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Cervical cancer [ICD-11: 2C77]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Cervical | |
The Specific Disease | Cervical cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.345734004; Fold-change: -0.049608938; Z-score: -0.166248044 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Uterine cancer [ICD-11: 2C78]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Endometrium | |
The Specific Disease | Uterine cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.001385853; Fold-change: 0.067334425; Z-score: 0.152081835 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.354861587; Fold-change: -0.327056014; Z-score: -0.929317632 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Prostate cancer [ICD-11: 2C82]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Prostate | |
The Specific Disease | Prostate cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.3644208; Fold-change: -0.229524506; Z-score: -0.380870565 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Bladder cancer [ICD-11: 2C94]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bladder | |
The Specific Disease | Bladder cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.005674059; Fold-change: -1.257324423; Z-score: -2.049440451 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Retina cancer [ICD-11: 2D02]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Uvea | |
The Specific Disease | Retinoblastoma tumor | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.002329625; Fold-change: -0.210164449; Z-score: -1.148894756 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Thyroid cancer [ICD-11: 2D10]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Thyroid | |
The Specific Disease | Thyroid cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.015374496; Fold-change: -0.319937123; Z-score: -0.422489008 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.001631218; Fold-change: 0.076546714; Z-score: 0.128533682 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Adrenal cancer [ICD-11: 2D11]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Adrenal cortex | |
The Specific Disease | Adrenocortical carcinoma | |
The Expression Level of Disease Section Compare with the Other Disease Section | p-value: 0.415860724; Fold-change: -0.202615461; Z-score: -0.567346037 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Head and neck cancer [ICD-11: 2D42]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Head and neck | |
The Specific Disease | Head and neck cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 3.48E-14; Fold-change: -0.647032029; Z-score: -0.778337569 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Pituitary cancer [ICD-11: 2F37]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Pituitary | |
The Specific Disease | Pituitary gonadotrope tumor | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.177027061; Fold-change: 0.440620349; Z-score: 1.078664346 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Pituitary | |
The Specific Disease | Pituitary cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.011812526; Fold-change: 0.402855648; Z-score: 1.136818895 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 03
Thrombocytopenia [ICD-11: 3B64]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Thrombocytopenia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.164692605; Fold-change: 0.306015177; Z-score: 2.917723025 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 04
Lupus erythematosus [ICD-11: 4A40]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Lupus erythematosus | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.160823912; Fold-change: -0.041599592; Z-score: -0.10423713 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Autoimmune disease [ICD-11: 4A4Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral monocyte | |
The Specific Disease | Autoimmune uveitis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.003990889; Fold-change: -0.212237911; Z-score: -1.02247083 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 05
Hyperlipoproteinaemia [ICD-11: 5C80]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Familial hypercholesterolemia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.729031358; Fold-change: -0.002339739; Z-score: -0.008971821 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 06
Schizophrenia [ICD-11: 6A20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Superior temporal cortex | |
The Specific Disease | Schizophrenia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.590381771; Fold-change: 0.076709251; Z-score: 0.633074754 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 08
Multiple sclerosis [ICD-11: 8A40]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Spinal cord | |
The Specific Disease | Multiple sclerosis | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.339474391; Fold-change: -0.058653767; Z-score: -0.163399879 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Plasmacytoid dendritic cells | |
The Specific Disease | Multiple sclerosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.231347716; Fold-change: 0.455635147; Z-score: 1.059625839 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Epilepsy [ICD-11: 8A60]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peritumoral cortex | |
The Specific Disease | Epilepsy | |
The Expression Level of Disease Section Compare with the Other Disease Section | p-value: 0.140242702; Fold-change: -0.577465457; Z-score: -2.115352885 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Cerebral ischaemic stroke [ICD-11: 8B11]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Cardioembolic Stroke | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.290174239; Fold-change: -0.022015206; Z-score: -0.118569253 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Peripheral blood | |
The Specific Disease | Ischemic stroke | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.345010718; Fold-change: 0.091438346; Z-score: 0.447284726 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 1
HIV [ICD-11: 1C60-1C62]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | White matter | |
The Specific Disease | HIV | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.083904363; Fold-change: -0.102806679; Z-score: -0.601202519 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Influenza [ICD-11: 1E30]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Influenza | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.570012539; Fold-change: 0.014892846; Z-score: 0.06072158 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Chronic hepatitis C [ICD-11: 1E51.1]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Chronic hepatitis C | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.33670919; Fold-change: -0.113133125; Z-score: -0.786218208 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Sepsis [ICD-11: 1G40-1G41]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Sepsis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.571000136; Fold-change: 0.019826642; Z-score: 0.070614896 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Septic shock [ICD-11: 1G41]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Septic shock | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.08996159; Fold-change: -0.066621954; Z-score: -0.207458618 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Pediatric respiratory syncytial virus infection [ICD-11: CA40.11]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Pediatric respiratory syncytial virus infection | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.164764309; Fold-change: -0.016702498; Z-score: -0.100450506 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 11
Essential hypertension [ICD-11: BA00]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Essential hypertension | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.404421238; Fold-change: -0.076886403; Z-score: -4.941160538 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Myocardial infarction [ICD-11: BA41]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Myocardial infarction | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.051581685; Fold-change: 0.23189577; Z-score: 0.594795506 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Coronary artery disease [ICD-11: BA8Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Coronary artery disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.179643487; Fold-change: -0.246267417; Z-score: -1.468327955 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Aortic stenosis [ICD-11: BB70]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Calcified aortic valve | |
The Specific Disease | Aortic stenosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.222126141; Fold-change: 0.294382577; Z-score: 0.893994387 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Arteriosclerosis [ICD-11: BD40]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Arteriosclerosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.885425763; Fold-change: 0.03950334; Z-score: 0.182468621 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Aneurysm [ICD-11: BD50]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Intracranial artery | |
The Specific Disease | Aneurysm | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.099496449; Fold-change: -0.107553045; Z-score: -0.262160942 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 12
Immunodeficiency [ICD-11: 4A00-4A20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Immunodeficiency | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.033956855; Fold-change: 0.187194317; Z-score: 1.523728854 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Apnea [ICD-11: 7A40]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Hyperplastic tonsil | |
The Specific Disease | Apnea | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.037096291; Fold-change: -0.25612559; Z-score: -1.968075476 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Olive pollen allergy [ICD-11: CA08.00]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Olive pollen allergy | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.086119151; Fold-change: 0.117471138; Z-score: 1.381634816 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Chronic rhinosinusitis [ICD-11: CA0A]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Sinus mucosa | |
The Specific Disease | Chronic rhinosinusitis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.316251629; Fold-change: 0.09873195; Z-score: 0.282647993 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Chronic obstructive pulmonary disease [ICD-11: CA22]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Lung | |
The Specific Disease | Chronic obstructive pulmonary disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.513249565; Fold-change: -0.028829707; Z-score: -0.087820065 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Small airway epithelium | |
The Specific Disease | Chronic obstructive pulmonary disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.007670236; Fold-change: -0.499952426; Z-score: -0.662223305 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Asthma [ICD-11: CA23]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Nasal and bronchial airway | |
The Specific Disease | Asthma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 5.59E-07; Fold-change: -0.283948459; Z-score: -0.222916785 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Human rhinovirus infection [ICD-11: CA42]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Nasal Epithelium | |
The Specific Disease | Human rhinovirus infection | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.979233674; Fold-change: -0.036684358; Z-score: -0.105191898 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Idiopathic pulmonary fibrosis [ICD-11: CB03.4]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Lung | |
The Specific Disease | Idiopathic pulmonary fibrosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.356082728; Fold-change: 0.057857538; Z-score: 0.135520535 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 13
Periodontal disease [ICD-11: DA0C]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Gingival | |
The Specific Disease | Periodontal disease | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.012251837; Fold-change: -0.324126129; Z-score: -0.476765602 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Eosinophilic gastritis [ICD-11: DA42.2]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Gastric antrum | |
The Specific Disease | Eosinophilic gastritis | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.095313105; Fold-change: 0.247413617; Z-score: 1.360766367 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Liver failure [ICD-11: DB99.7-DB99.8]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Liver | |
The Specific Disease | Liver failure | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.017481405; Fold-change: -0.298951991; Z-score: -1.220916592 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Ulcerative colitis [ICD-11: DD71]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Colon mucosal | |
The Specific Disease | Ulcerative colitis | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.742423766; Fold-change: -0.058447298; Z-score: -0.234895268 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Irritable bowel syndrome [ICD-11: DD91.0]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Rectal colon | |
The Specific Disease | Irritable bowel syndrome | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.178049459; Fold-change: -0.06551847; Z-score: -0.255841339 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 14
Atopic dermatitis [ICD-11: EA80]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Atopic dermatitis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.080307916; Fold-change: -0.132912034; Z-score: -0.685778056 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Psoriasis [ICD-11: EA90]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Psoriasis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.245279233; Fold-change: -0.172649165; Z-score: -0.302502826 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 1.89E-41; Fold-change: 0.537445296; Z-score: 2.230434432 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Vitiligo [ICD-11: ED63.0]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Vitiligo | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.354648452; Fold-change: 0.093244905; Z-score: 0.516508092 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Alopecia [ICD-11: ED70]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin from scalp | |
The Specific Disease | Alopecia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.145406491; Fold-change: 0.060466136; Z-score: 0.229385077 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Sensitive skin [ICD-11: EK0Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Sensitive skin | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.49598425; Fold-change: 0.317323593; Z-score: 0.581470041 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 15
Osteoarthritis [ICD-11: FA00-FA0Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Synovial | |
The Specific Disease | Osteoarthritis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.596294683; Fold-change: 0.00074721; Z-score: 0.002162212 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Arthropathy [ICD-11: FA00-FA5Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Arthropathy | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.648891763; Fold-change: -0.016919758; Z-score: -0.07783617 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Arthritis [ICD-11: FA20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Arthritis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.343640269; Fold-change: 0.001201018; Z-score: 0.004816102 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Rheumatoid arthritis [ICD-11: FA20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Synovial | |
The Specific Disease | Rheumatoid arthritis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.246599282; Fold-change: 0.175239639; Z-score: 0.34416949 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Ankylosing spondylitis [ICD-11: FA92.0Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Pheripheral blood | |
The Specific Disease | Ankylosing spondylitis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.175614566; Fold-change: 0.113731949; Z-score: 0.480934006 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Osteoporosis [ICD-11: FB83]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bone marrow | |
The Specific Disease | Osteoporosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.040103439; Fold-change: 0.880556385; Z-score: 4.944408728 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 16
Endometriosis [ICD-11: GA10]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Endometrium | |
The Specific Disease | Endometriosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.888712642; Fold-change: -0.093771761; Z-score: -0.25632236 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Interstitial cystitis [ICD-11: GC00.3]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bladder | |
The Specific Disease | Interstitial cystitis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.001496637; Fold-change: -1.138266278; Z-score: -2.988495247 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 19
Preterm birth [ICD-11: KA21.4Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Myometrium | |
The Specific Disease | Preterm birth | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.710402149; Fold-change: -0.05864976; Z-score: -0.66030011 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 2
Acute myelocytic leukemia [ICD-11: 2A60]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bone marrow | |
The Specific Disease | Acute myelocytic leukemia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.114727383; Fold-change: -0.048984373; Z-score: -0.251540805 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Myeloma [ICD-11: 2A83]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bone marrow | |
The Specific Disease | Myeloma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.021335399; Fold-change: 0.095198056; Z-score: 0.629065446 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Peripheral blood | |
The Specific Disease | Myeloma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.350893053; Fold-change: 0.086227385; Z-score: 0.462021531 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Oral cancer [ICD-11: 2B6E]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Oral | |
The Specific Disease | Oral cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.015079995; Fold-change: -0.213915921; Z-score: -0.382167512 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 4.78E-09; Fold-change: -0.716067055; Z-score: -0.786617541 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Esophagal cancer [ICD-11: 2B70]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Esophagus | |
The Specific Disease | Esophagal cancer | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.740405247; Fold-change: -0.275644435; Z-score: -0.514688212 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Rectal cancer [ICD-11: 2B92]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Rectal colon | |
The Specific Disease | Rectal cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.957525087; Fold-change: -0.117135726; Z-score: -0.225945024 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 1.05E-05; Fold-change: -1.049229149; Z-score: -3.975480307 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Skin cancer [ICD-11: 2C30-2C3Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Skin cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 4.76E-07; Fold-change: -0.485984665; Z-score: -0.748907119 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 1.11E-14; Fold-change: 0.232655645; Z-score: 0.637166891 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Renal cancer [ICD-11: 2C90-2C91]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Kidney | |
The Specific Disease | Renal cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.292109361; Fold-change: -0.24493717; Z-score: -0.235064848 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 2.68E-15; Fold-change: -0.803082274; Z-score: -1.443359315 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Ureter cancer [ICD-11: 2C92]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Urothelium | |
The Specific Disease | Ureter cancer | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.931225005; Fold-change: 0.052255676; Z-score: 0.241930943 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 20
Simpson golabi behmel syndrome [ICD-11: LD2C]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Adipose | |
The Specific Disease | Simpson golabi behmel syndrome | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.899369522; Fold-change: -0.100631075; Z-score: -0.675234335 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Tuberous sclerosis complex [ICD-11: LD2D.2]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Perituberal | |
The Specific Disease | Tuberous sclerosis complex | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.146893491; Fold-change: -0.103328516; Z-score: -0.998804448 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 3
Anemia [ICD-11: 3A00-3A9Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Bone marrow | |
The Specific Disease | Anemia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.821558408; Fold-change: 0.112263687; Z-score: 0.543197774 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Sickle cell disease [ICD-11: 3A51.0-3A51.3]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Sickle cell disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.279092273; Fold-change: 0.212385394; Z-score: 0.715113871 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Thrombocythemia [ICD-11: 3B63]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Thrombocythemia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.54298711; Fold-change: -0.10208841; Z-score: -0.524650255 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 4
Scleroderma [ICD-11: 4A42.Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Scleroderma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.043075833; Fold-change: 0.191472642; Z-score: 0.883395266 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Sjogren syndrome [ICD-11: 4A43]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Salivary gland | |
The Specific Disease | Sjogren syndrome | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.472694164; Fold-change: -0.305825893; Z-score: -1.034130527 | |
The Expression Level of Disease Section Compare with the Adjacent Tissue | p-value: 0.035986035; Fold-change: -0.263974907; Z-score: -1.937527694 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Behcet disease [ICD-11: 4A62]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Peripheral blood | |
The Specific Disease | Behcet disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.743109111; Fold-change: 0.129191687; Z-score: 0.49013054 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Autosomal dominant monocytopenia [ICD-11: 4B04]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Autosomal dominant monocytopenia | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.581617339; Fold-change: -0.080421466; Z-score: -0.364055736 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 5
Type 2 diabetes [ICD-11: 5A11]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Liver | |
The Specific Disease | Type 2 diabetes | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.087601114; Fold-change: -0.165683016; Z-score: -0.989682647 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Polycystic ovary syndrome [ICD-11: 5A80.1]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Vastus lateralis muscle | |
The Specific Disease | Polycystic ovary syndrome | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.124863857; Fold-change: -0.16439822; Z-score: -0.938655765 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Obesity [ICD-11: 5B81]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Subcutaneous Adipose | |
The Specific Disease | Obesity | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.084778678; Fold-change: -0.122947928; Z-score: -0.787037488 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Pompe disease [ICD-11: 5C51.3]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Biceps muscle | |
The Specific Disease | Pompe disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.917500139; Fold-change: -0.003189095; Z-score: -0.024864192 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Batten disease [ICD-11: 5C56.1]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Batten disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.977461639; Fold-change: 0.025667446; Z-score: 0.153646914 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 6
Autism [ICD-11: 6A02]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Autism | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.017930814; Fold-change: -0.115092535; Z-score: -0.528873069 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Anxiety disorder [ICD-11: 6B00-6B0Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Anxiety disorder | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.028470494; Fold-change: 0.051639545; Z-score: 0.251367933 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
ICD Disease Classification 8
Parkinson disease [ICD-11: 8A00]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Substantia nigra | |
The Specific Disease | Parkinson disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.470919115; Fold-change: -0.088008934; Z-score: -0.243685685 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Huntington disease [ICD-11: 8A01]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Huntington disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.243429319; Fold-change: 0.115488831; Z-score: 0.793933744 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Alzheimer disease [ICD-11: 8A20]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Entorhinal cortex | |
The Specific Disease | Alzheimer disease | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.606874505; Fold-change: -0.03918006; Z-score: -0.140924602 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Seizure [ICD-11: 8A60-8A6Z]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Whole blood | |
The Specific Disease | Seizure | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.628096184; Fold-change: 0.137136895; Z-score: 0.534471432 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Lateral sclerosis [ICD-11: 8B60.4]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Skin | |
The Specific Disease | Lateral sclerosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.301723855; Fold-change: -0.165174188; Z-score: -0.477732012 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Cervical spinal cord | |
The Specific Disease | Lateral sclerosis | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.683230296; Fold-change: 0.004772728; Z-score: 0.034888825 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Muscular atrophy [ICD-11: 8C70]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Muscle | |
The Specific Disease | Muscular atrophy | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.019006642; Fold-change: -0.251477117; Z-score: -0.966091571 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
Myopathy [ICD-11: 8C70.6]
Differential expression pattern of antigen in diseases | ||
The Studied Tissue | Muscle | |
The Specific Disease | Myopathy | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 0.356468651; Fold-change: -0.119099861; Z-score: -0.303362323 | |
Disease-specific Antigen Abundances | Click to View the Clearer Original Diagram | |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.